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Abstract 
 
Review and Extension for the O’Brien Fleming Multiple Testing procedure 
by 
Hanan Hammouri, MS. 
Advisor: Dr. Roy Sabo 
O'Brien and Fleming (1979) proposed a straightforward and useful multiple testing procedure 
(group sequential testing procedure) for comparing two treatments in clinical trials where subject 
responses are dichotomous (e.g. success and failure). O'Brien and Fleming stated that their group 
sequential testing procedure has the same Type I error rate and power as that of a fixed one-stage 
chi-square test, but gives the opportunity to terminate the trial early when one treatment is clearly 
performing better than the other. We studied and tested the O'Brien and Fleming procedure 
specifically by correcting the originally proposed critical values. Furthermore, we updated the 
O’Brien Fleming Group Sequential Testing procedure to make it more flexible via three 
extensions. The first extension is combining the O’Brien Fleming Group Sequential Testing 
procedure with the Optimal allocation, where the idea is to allocate more patients to the better 
treatment after each interim analysis. The second extension is combining the O’Brien Fleming 
Group Sequential Testing procedure with the Neyman allocation which aims to minimize the 
variance of the difference in sample proportions. The last extension is that we can allow for 
different sample weights for different stages, as opposed to equal allocation for different stages. 
Simulation studies showed that the O’Brien Fleming Group Sequential Testing procedure is 
relatively robust to the added features. 
 
 
 
1 
 
 
Chapter 1 : Introduction 
 
 
In the last few years, researchers have given a lot of attention to adaptive design methods in 
clinical trials due to their flexibility and efficiency.  There is no common definition for adaptive 
design. Usually, researchers use adaptive design to define design that allows for modification or 
changes to be done to the trial and/or statistical procedure in any stage of the trial without 
negatively impacting its validity and integrity.
6
 Modification or changes for the adaptive design 
are made “by design” therefore; adaptation is a design characteristic used to increase efficiency 
of the trial, not a solution for inadequate planning .
5 
The rational for the use of adaptive designs arise from the need to minimize the cost and 
maximize the safety of any trial. The two main factors that determine the cost of the clinical trial 
are the sample size and the duration that is needed for the clinical trial. Requiring a smaller 
sample size will decrease the trial costs associated with screening, treatment, and follow-up. 
Moreover, shorter duration allows earlier benefits from effective treatments and prevents the 
waste of resources on ineffective ones. Besides, duration has an essential role in ethical 
considerations. In other words, shorter duration exposes fewer patients to an ineffective or 
harmful treatment and gives more patients the chance to benefit from effective new treatments.
13 
Adaptive designs in clinical trials commonly fall under one of the following groups 
depending on the modifications or changes involved: 
6
 
 
 
2 
 
a) Adaptive randomization design: a design that allows modification of randomization 
schedules to enable a higher proportion of patients to be randomly assigned the treatment 
that is currently performing better. 
b) Group sequential design: a design that divides sample size into a number of groups so 
that the decision to stop the trial or continue is based on repeated significance tests of the 
accumulated data after each group is evaluated. 
c) Sample size re-estimation design: a design that re-estimates the sample size based on 
interim analysis results. 
d) Drop-the-loser design: a design that has two stages of a trial. In the first stage, k 
treatments and a control are tested. After that the design chooses the best treatment which 
is selected for continuation into the second stage along with the control. 
e) Adaptive dose-finding design: a design that identifies the minimum effective dose (MED) 
and/or the maximum tolerable dose (MTD) to determine the dose level for the next 
clinical trial phase. 
f) Biomarker-adaptive design: a design that allows for modification depending on the 
response of biomarkers such as genomic markers. 
g) Adaptive treatment-switching design: a design that allows switching patients’ treatment 
to the alternate if there is evidence of low efficacy or toxicity of the initial treatment. 
h) Hypothesis-adaptive design: a design that allows modifications in hypotheses based on 
interim analysis results. 
i) Adaptive seamless phase II/III trial design: a design that combines the patients of 
separate Phase II and Phase III trials into a single trial. This design uses data from 
patients enrolled before and after the adaptation in the final analysis. 
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j) Multiple adaptive designs: a design that is a combination of at least two of the adaptive 
designs mentioned above. 
Since adaptive designs have great flexibility, the designs included are not considered 
exclusive designs for adaptive design .
6
 
Even though these adaptive designs give numerous opportunities, statisticians warn against 
ignoring the challenges that come with these designs. Also it is of importance to overcome these 
challenges before the usage of adaptive designs becomes widespread so that the advantages 
offered by these designs can be achieved. 
These challenges are divided into three areas which are statistical, logistical, and procedural 
issues. Some of the statistical challenges are .
15 
 It is challenging to control Type I error rate. 
 It is challenging to interpret the findings and accept the inferences drawn from the 
adaptive designs. 
Some of the logistical challenges are: 
 It is challenging to deal with statistical methods for adaptive designs; this is because 
in many cases the technical issues and the calculations are more complex than ones 
associated with traditional designs. 
 It is challenging to maintain an interactive communication system between 
patients/investigators/study sites and the randomization center to achieve optimal 
implementation of any adaptive designs. 
 
And some of the Procedural challenges are: 
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 It is challenging to maintain trial integrity while following the procedures relating to 
data review, decision making, and implementation of decisions during adaptive trials. 
 It is challenging to make certain decisions because adaptive designs give these 
decisions a new character by taking them outside the traditional framework for any 
procedure in traditional trials. This generates the need for the individuals with 
expertise relevant to the type of decisions to be made, including reviewing adaptation 
performance and approving changes if necessary. 
In this thesis we addressed one among particularly well-known class of adaptive designs 
known as “Group Sequential Methods.” These designs divide sample size into a number of 
equal-sized groups so that the decision to stop the trial or continue is based on repeated 
significance tests of the accumulated data after each group is evaluated. 
In other words, the general rule is to determine the maximum sample size N that is needed 
before starting the trial. Then, at periodic intervals throughout the trial, up to K interim analyses 
are performed to determine whether the trial should stop early before reaching the maximum 
sample size N. Specifically, our focus is on the O'Brien Fleming Multiple Testing procedure.
25 
O'Brien and Fleming proposed a straightforward and useful multiple testing procedure for 
comparing two treatments in clinical trials where subject responses are dichotomous (e.g. success 
and failure).
25
 O'Brien Fleming stated that their multiple testing procedure (group sequential 
testing (GST) procedure) has the same Type I error rate and power as that of a fixed one-stage 
chi-square test, but gives the opportunity to terminate the trial early when one treatment is clearly 
performing better than the other. 
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Though this method is widely used, there are two issues: first, the critical values provided by 
O’Brien and Fleming are not monotonic; we studied and corrected them using the O’Brien 
Fleming method. Second, there is some doubt as to whether the method maintains the desired 
Type I error rate and the desired power since (i) it reuses data from earlier stages, (ii) its critical 
values are based on simulations of an approximate test statistic, and (iii) the critical values are 
not dependent upon the marginal proportions of the two groups under consideration. We found 
that the Type I error for the O’Brien Fleming GST procedure was studied by Gary and Stuart12, 
who found that the procedure maintain the desired Type I error. Unfortunately they didn’t 
mention the process they used to check the O’Brien Fleming GST procedure and only used one 
scenario. Thus, we studied and tested the procedure and showed that the procedure works well as 
the regular chi-square test for a variety of scenarios, such as various levels of marginal 
proportions, balanced, and unbalanced designs.   
To make the O’Brien Fleming GST procedure even more useful in practice researchers 
expanded the procedure in several directions. Seigel and Milton
31
 demonstrated that the GST 
procedure and the stopping bounds presented by O'Brien and Fleming
25
 in clinical trials of 
severe diseases can also be applied, without adjustment, to chronic-disease trials. Another 
direction is to extend the procedure to more the two treatments; Betensky
3
 used the stopping 
bounds for the O’Brien Fleming GST procedure with a new sequential procedure for comparing 
three treatments. This procedure starts with a sequential test to test the overall treatment 
difference and eliminates the worst treatment, and then carries on with a sequential test of the 
remaining two treatments to choose the better treatment. On the other hand, after Kung-Jong Lui 
tested the procedure with the presence of correlation between the treatments and demonstrated 
that being able to maintain a uniform medical test procedure between the two treatments for each 
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analysis, the actual Type I error of the O'Brien Fleming GST procedure may become 
conservative
22
. He provided a direct generalization of the O'Brien Fleming GST procedure to 
accommodate more than two treatment groups. He also provided a table that summarizes the 
critical values for a-levels equal to .05 and .10 in the situation where the number of treatment 
groups ranges from 2 to 10 and the number of sequential tests ranges from 1 to 10
23
. 
Furthermore, we updated the O’Brien Fleming GST procedure to make it more flexible using 
three extensions. The first extension is combining the O’Brien Fleming GST procedure with the 
optimal allocation. After each stage in the O’Brien Fleming Group Sequential Testing procedure, 
we calculate the new allocation for both groups depending on the optimality criteria, since we 
use the success counts for the two groups from the previous stage, the allocation may change 
from stage to stage through the study. The idea behind the optimal allocation is to allocate more 
patients to the better treatment
30
. The second extension is combining the O’Brien Fleming Group 
Sequential Testing procedure with the Neyman allocation. After each stage in the O’Brien 
Fleming GST procedure we calculate the new allocation for both groups depending on the 
Neyman criteria, since we use the success and the failure counts for the two groups from the 
previous stage, the allocation also may change from stage to stage through the study. The idea 
behind Neyman allocation is to minimize the variance of the difference in sample proportions
30
. 
The last extension is that we are allowing for different sample weights for different stages where 
the original O’Brien Fleming GST with an equal allocation requires for equal sample sizes for 
different stages. 
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1.1 Outline 
 
The first chapter covers the O’Brien Fleming GST procedure. We showed that the stopping 
bounds were incorrect because the number of simulation iterations O’Brian and Fleming used to 
estimate the stopping bounds was insufficient. Using the same method they used to estimate 
these stopping bounds with a much larger number of iterations, we estimated new stopping 
bounds. Then we illustrated how the O’Brien Fleming GST procedure works using two examples 
(one example is with a significant difference between the groups and the other example is with 
no significant difference between the two groups). 
In the second chapter we use Monte Carlo simulation to test the Type I error and the power 
for the O’Brien Fleming procedure. Monte Carlo simulation is a great alternative to the 
theoretical approach to reach statistical proof. There are many situations where the theoretical 
approach is difficult to implement, much less to find an exact solution. Since O’Brian and 
Fleming used an approximation distribution to prove that their O’Brien Fleming procedure has 
the same Type I error rate as that of a fixed one-stage chi-square test, we used the Monte Carlo 
simulation to determine if the Type I error rate is affected by various values for success 
probability (.1, .2, .3, .4 and .5) for both balanced and unbalanced cases with alpha= .01 and .05.   
Likewise, we used the Monte Carlo simulation to test if the power is affected by different values 
for success probabilities ((P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.4) and (P1=.4, P2=.521) ) 
with alpha =.01 for balanced and unbalanced cases and ((P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, 
P2=.3), (P1=.345, P2= .5)) and .05 for balanced and unbalanced cases. Also, in this chapter we 
used ANOVA to show that choosing the random seed in the Monte Carlo simulation does not 
affect the result of Type I error. 
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Chapter three covers the following: we extended the O’Brien Fleming GST procedure in 
the balanced case in three ways. The first extension is combining the O’Brien Fleming GST 
procedure with the optimal allocation. The second extension is combining the O’Brien Fleming 
GST procedure with the Neyman allocation. The last extension involves changing the sample 
size from stage to stage in the procedure. Also, we will tested Type I error and power for each 
extension, to check if the procedure got affected by any extension we applied. We used all the 
scenarios we used in the previous chapter for testing the Type I error and power.  
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Chapter 2 : The O’Brien Fleming Group Sequential Testing (GST) procedure  
2.1 Introduction  
 
O'Brien and Fleming (1979) proposed a straightforward and useful multiple (group 
sequential) testing procedure for comparing two treatments in clinical trials where subject 
responses are dichotomous (e.g. success or failure). They claimed their GST procedure has the 
same Type I error rate and power as that of a fixed one-stage chi-square test, but gives the 
opportunity to terminate the trial early when there is sufficient statistical evidence that one 
treatment is clearly performing better than the other. In this chapter we will cover the O’Brien 
Fleming GST procedure. Also we will provide a correction for the estimates of the stopping 
bounds. 
2.2 The O’Brien Fleming GST procedure 
 
The GST procedure can be used in any clinical trial which compares two treatments with 
binary outcomes. The data must be collected independently on each treatment and the response 
should be binary. 
The procedure is as follows: the data are reviewed and tested periodically with m1 subjects 
receiving treatment 1, and m2 subjects receiving treatment 2 for each test. Since there are K 
tests, the maximum number of subjects is  N = K m1 + m2 ; all of these values are fixed in 
advance.  
1. First, m1 and m2 subjects are assigned to treatments 1 and 2, respectively. The 
experiment is terminated and the hypothesis of no difference between treatments 
rejected if       
2
1
l /   P ,  ,K K   where  
2
1
  is the usual Pearson chi-square 
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statistic, α is the size of the test, and P (K, α) is a critical value obtained from the 
O’Brian Fleming Table that is generated in such a way that the total Type I error will 
not exceed the desired α (Table 2-1).  
2. Otherwise, if the critical value is not exceeded, the next m1 + m2 subjects are 
randomized and their measurements are observed. In general, for the kth test, the study 
is terminated and the null hypothesis is rejected if      
2   P ,  ,
k
k / K K   where 
 
2
k
  is the usual Pearson chi-square statistic based on all data collected up to the kth 
test. 
3.  If after completing K tests,  
2
K
  does not exceed  P ,  K  , the study is terminated 
with the conclusion that the hypothesis of no difference cannot be rejected at the α 
level of significance. (Figure 2-1) 
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Figure 2-1: The O’Brien Fleming procedure 
 
2.3 Studying the Stopping Bound of the O’Brien Fleming procedure. 
 
In Figure 2-2 we can see the O’Brien-Fleming cutoff values do not increase 
monotonically, which should be the case for any interim analysis; i.e. every time 
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we increase the number of interim stages there should be a larger critical value, 
which will make it harder to reject the null hypothesis. So we started studying the 
method that O’Brien and Fleming used to find their bounds. Then we found the 
cause of the problem.  
2.3.1 Method used to estimate the Stopping Bound 
 
In addition to the previously established notation, for n=1, . . . ,N and k=1, 2, let πk  
correspond to the true (unknown) success rate for treatment k, and let ykn be the number of  
successes with treatment k occurring after the n – 1 test but prior to the nth test. Further, define 
Skn= ∑  
 
 kl , and pkn=Skn/nmk. The hypothesis being tested (Hо) is that π1=π2= π, where π is an 
unknown constant between 0 and 1. Then, χ2 (n) can be represented as χ2 (n)=Zn
2
,  
Where    
       
√   ̂         
 and where 
    ̂(p1n -p2n)=
       
      
   
       
        
  
is the pooled estimate of variance. An approximate expression for Zn, obtained by replacing the 
estimate of variance with its expectation, is given by 
Zn
*
= 
∑       
√ 
 , 
where Ui=NID(0, 1), i=1, . . . , N. Thus, approximate values for P(N,α) may be obtained by 
generating standard normal variates (U1, . . . , UN) and evaluating the percentiles of max{Tn}, 1 ≤ 
n ≤ N, where Tn=
 ∑    
 
   
 
 
  . Note that max{Tn} has the same distribution as max{[W(n/N)]
2
} , 
1< n < N, where {W(t)| 0≤  t ≤1} represents Brownian motion. Percentile estimates for the 
original O’Brien Fleming critical values based on 10,000 samples are listed in (Table 2.1). 
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Table 2-1: Values of       . 
  Number of stages (K) 
Alpha  1 2 3 4 5 
0.5 0.462 0.656 0.750 0.785 0.819 
0.1 2.670 2.859 2.907 2.979 3.087 
0.09 2.866 3.031 3.073 3.147 3.283 
0.08 3.077 3.197 3.240 3.338 3.467 
0.07 3.294 3.363 3.437 3.546 3.663 
0.06 3.576 3.652 3.683 3.853 3.889 
0.05 3.869 3.928 3.940 4.170 4.149 
0.04 4.289 4.231 4.264 4.477 4.584 
0.03 4.800 4.722 4.700 4.964 5.045 
0.02 5.490 5.392 5.462 5.555 5.789 
0.01 6.667 6.574 6.503 6.864 6.838 
0.005 7.885 7.818 7.442 7.890 8.037 
0.001 10.062 10.240 10.202 11.062 10.602 
 
2.4 Correction for the estimate of the Stopping Bound 
 
We hypothesized that the O’Brien Fleming stopping bounds are off because of 
the simulation technique: 10,000 simulations was not enough to accurately 
estimate the critical values. We reproduced the stopping bounds using the same 
method (Figure 2-4) based on 10,000,000 simulations (Table 2-2), which are now 
clearly monotonically increasing with K (Figure 2-3). Since the method depends on 
the simulations group and how the software generates it, we calculated the standard 
deviations for the stopping bounds by using ten different simulations groups (Table 
A.3)     
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Figure 2-2: Examples for original       , which do not increase monotonic. 
 
Table2-2:  The corrected values of        . 
 Number of stages (K) 
Alpha 1 2 3 4 5 
0.5 0.4547 0.6546 0.7439 0.8013 0.8431 
0.1 2.7042 2.8195 2.9247 3.0047 3.0650 
0.09 2.8730 2.9817 3.0877 3.1668 3.2275 
0.08 3.0633 3.1646 3.2700 3.3498 3.4114 
0.07 3.2814 3.3754 3.4799 3.5594 3.6220 
0.06 3.5348 3.6207 3.7251 3.8034 3.8669 
0.05 3.8399 3.9152 4.0191 4.0961 4.1602 
0.04 4.2177 4.2809 4.3836 4.4599 4.5243 
0.03 4.7099 4.7622 4.8587 4.9341 5.0008 
0.02 5.4106 5.4537 5.5396 5.6148 5.6827 
0.01 6.6393 6.6618 6.7353 6.8021 6.8764 
0.005 7.8863 7.9019 7.9529 8.0094 8.0803 
0.001 10.8280 10.8527 10.8618 10.9263 10.9820 
4
5
6
7
8
9
10
11
12
K=1 K=2 K=3 K=4 K=5
O'Brien .03
O'Brien .01
O'Brien .005
O'Brien .001
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Figure 2-3: Examples for       , comparing the original values to the corrected one. 
 
4
5
6
7
8
9
10
11
12
K=1 K=2 K=3 K=4 K=5
O'Brien .03
Corrected values .03
O'Brien .01
Corrected values .01
O'Brien .005
Corrected values .005
O'Brien .001
Corrected values .001
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Figure 2-4: Estimating the stopping bound algorithm. 
 
2.5 The O’Brien Fleming procedure illustrating examples   
 
      In this section we will provide two examples to demonstrate how the O’Brien Fleming GST 
procedure works when there is a significant difference or insignificant difference. For illustration 
when there is a significant difference between the groups, we used a real clinical trial data for 60 
subjects for each group (120 total subjects), then we used the O’Brien-Fleming procedure for 
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different number of interim analysis (K=1, 2, 3, 4 and 5), and specified which case required the 
fewest subjects. 
 Case 1: m1=m2=60, K =1. 
 Case 2: m1=m2=30, K =2. 
 Case 3: m1=m2=20, K =3. 
 Case 4: m1=m2=15, K =4. 
 Case 5: m1=m2=12, K =5. 
For the first case K=1 and m1=m2=60, so we are using P (K=1, α=.05) =3.84. We used all 
of the sample size at once. Then we used the GST procedure (that is the same as chi-square when 
K=1). The O’Brien Fleming statistic test is equal 9.025 which is greater than 3.84. So the 
statistic for this interim analysis was significant, indicating a difference between the treatments 
(Table 2-3). 
Table 2-3: Case 1 result. 
Case1 analysis results. 
k alpha Total Sample size (k/K)Chi-square 
1 3.84 120 9.025 
 
For the second case, we divided the sample size into two equal clusters, so K=2, 
m1=m2=30 and we are using P (K=2, α=.05) =3.92. Then we used the GST procedure but we 
could not terminate the trial in first interim analysis, because the statistic didn’t exceed the P 
(K=2, α=.05) (statistic equals 2.143 which is less than 3.92). Therefore we had to use the entire 
sample size of 60 for each group. The statistic for the second interim analysis was also 
significant. The O’Brien Fleming test statistic is equal 9.025 which is greater than 3.92, 
indicating a difference between the treatments (Table 2.4). 
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Table 2-4: Case 2 result. 
Case2 analysis results. 
k alpha Total sample size (k/K)Chi -square 
1 3.92 60 2.143 
2 3.92 120 9.025 
 
In the third case, we divided the sample size into three equal clusters, and then we used the 
GST procedure with K=3, m1=m2=20 and P (K=3, α=.05) =4.02. The Chi-square statistic 
exceeded the cutoff (which equals 4.02) in the second interim analysis (the test statistic equals 
4.056). So the trial was terminated and only 80 subjects were needed in total to conclude that 
there is a significant difference between the two treatments (Table 2-5). 
Table 2-5: Case 3 result. 
Case3 analysis results. 
K alpha Total sample size (k/K)Chi -square 
1 4.02 40 1.742 
2 4.02 80 4.056 
 
In the fourth case, we divided the sample size into four equal clusters. We used the GST 
procedure with K=4, m1=m2=15 and P (K=4, α=.05) =4.10. The Chi-square statistic exceeded 
the cutoff (which equals 4.10) in the third interim analysis (the test statistic equals 5.735). So the 
trial was terminated and only 90 subjects were needed in total to conclude that there is a 
significant difference between the two treatments (Table 2-6). 
Table 2-6: Case 4 result. 
Case4 analysis results. 
k alpha Total sample size (k/K)Chi –square 
1 4.10 30 0.600 
2 4.10 60 2.143 
3 4.10 90 5.735 
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For the fifth case, we divided the sample size into five equal clusters. We used the GST 
procedure with K=4, m1=m2=15 and P (K=4, α=.05) =4.10. The O’Brien Fleming statistic 
(which equals 4.536) exceeded the cutoff of 4.16 in the fourth interim analysis. So the trial was 
terminated and only 96 subjects were needed to conclude that there is a significant difference 
between the two treatments (Table 2-7). 
Table 2-7: Case 5 result. 
Case5 analysis results. 
k alpha Total sample size (k/K)Chi –square 
1 4.16 24 0.120 
2 4.16 48 1.366 
3 4.16 72 3.249 
4 4.16 96 4.536 
 
As we can see, the third case found there was a difference with just 80 subjects in total, 
which is less than the 120 subjects that would have been used in a conventional clinical trial 
(Figure 2-5). 
 
Figure 2-5: Total patients needed for each case to find a significant difference. 
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The following example is to illustrate how the procedure works when there is no difference 
between the two treatments. We simulated the two groups from the same distribution to make 
sure that there is no difference between the means. So we have data for 60 subjects for each 
group that been simulated from binomial distribution with P=.4 (120 total subjects). We used the 
O’Brien Fleming GST procedure for different number of interim analysis (K=1, 2, 3, 4 and 5). 
Again we used: 
 Case 1: m1=m2=60, K =1. 
 Case 2: m1=m2=30, K =2. 
 Case 3: m1=m2=20, K =3. 
 Case 4: m1=m2=15, K =4. 
 Case 5: m1=m2=12, K =5. 
For all interim analysis in all cases we failed to find a difference (which is expected); all 
(k/K) Chi-square values are less than the alpha values (Table 2-8). 
Table 2-8: The second example results. 
Case1 analysis results. 
K alpha Total Sample size (k/K)Chi-square 
1 3.84 120 0.0345 
Case2 analysis results. 
K alpha Total sample size (k/K)Chi -square 
1 3.92 60 0.1333 
2 3.92 120 0.0345 
Case3 analysis results. 
K alpha Total sample size (k/K)Chi -square 
1 4.02 40 0.0000 
2 4.02 80 0.0344 
3 4.02 120 0.0345 
Case4 analysis results. 
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K alpha Total sample size (k/K)Chi -square 
1 4.10 30 0.0000 
2 4.10 60 0.0333 
3 4.10 90 0.0000 
4 4.10 120 0.0345 
Case5 analysis results. 
K alpha Total sample size (k/K)Chi -square 
1 4.16 24 0.0336 
2 4.16 48 0.0334 
3 4.16 72 0.1372 
4 4.16 96 0.2894 
5 4.16 120 0.0345 
 
2.6 Conclusion  
 
In this chapter we reviewed the O’Brien Fleming GST procedure which is a type stage 
interim analysis. We showed that the stopping bounds were off because the number of simulation 
iterations O’Brian and Fleming used to estimate the stopping bounds was not enough. Using the 
same method they used with a much larger number of iterations, we estimated new stopping 
bounds. Then we illustrated how the O’Brien Fleming GST procedure works using two examples 
(one example is with a significant difference between the groups and the other example is with 
no significant difference between the two groups). 
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Chapter 3 : Validating the O’Brien Fleming procedure 
3.1 Introduction  
In the previous chapter we looked to the O’Brien Fleming GST procedure thoroughly. 
Even more, we corrected the boundary values. In this chapter, since there is some doubt as to 
whether the method maintains the desired Type I error rate, since it reuses data from earlier 
stages, and maintains the sample size for the desired power, we use simulations in order to 
examine these two issues.   
The statistical practice of hypothesis testing is well-known not only in statistics, but also all 
throughout the natural and social sciences. The hypothesis testing procedure can appear to be 
relatively varied with different types of test statistics, but the procedure is generally the same. 
Hypothesis testing contains the statement of a null hypothesis, mutually exclusive and 
complementary alternative hypothesis and the choice of a level of significance. The null 
hypothesis is either true or false. For example, when examining the usefulness of a treatment, the 
null hypothesis would be that the treatment has no effect on a disease. After setting the null 
hypothesis and selecting a level of significance, we collect data. Statistical analysis will 
determine whether or not we should reject the null hypothesis. 
In a perfect world we would at all times reject the null hypothesis when it is false, and we 
would fail to reject the null hypothesis when it is certainly true; but this is not the case. In 
hypothesis testing there are four scenarios: reject the null hypothesis when it is true, reject the 
null hypothesis when it is false, fail to reject the null hypothesis when it is true and fail to reject 
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the null hypothesis when it is false.  Two of these outcomes result in a wrong decision: reject the 
null hypothesis when it is true (this is called Type I error) and fail to reject the null hypothesis 
when it is false (this called Type II error). While we cannot necessarily avoid such errors, these 
errors can be controlled and minimized. 
 
Figure 3-1: Consequences of Decisions in Statistical Hypothesis Testing 
 
 In this chapter we are looking to see if the O’Brien Fleming procedure is robust to 
different levels of P1and P2 with a balanced or unbalanced case, so we are interested in the Type 
I error and power (1-Type II error) for the O’Brien Fleming GST procedure. For Type I error, 
our conclusion is that the treatment does in fact have some effect on a disease, but since the null 
hypothesis is true, then in reality the drug does not treat the disease at all. The drug is falsely 
claimed to have a positive effect on a disease. Type I errors can be controlled through the value 
of alpha, which is the level of significance that we selected. Alpha is the desired maximum 
probability of expecting a Type I error. For a 95% confidence level, the value of alpha is 0.05. 
This means that there is 5% likelihood that we will reject the null hypothesis when it is true. For 
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example, if we conduct 20 hypothesis tests (with the null hypothesis as being true), we will reject 
the null hypothesis for one of these tests as a result of Type I error.  
We will also investigate the power of the O’Brien Fleming (reject the null hypothesis when 
it is false, power=1-Type II error), which measures the sample size capability to catch true 
difference between two groups. For example if we have 80% power, that means that if there is a 
difference between the groups, then the test statistic has a 80% probability to find a statistically 
significant difference between groups. 
In this chapter we will use Monte Carlo simulation to test the Type I error and the power 
for the O’Brien Fleming procedure. Monte Carlo simulation gives researchers an alternative to 
the theoretical approach. There are many situations where the theoretical approach is difficult to 
implement, much less to find an exact solution. This is similar to how O’Brian and Fleming used 
an approximation distribution to prove that their O’Brien Fleming procedure has the same Type I 
error rate as that of a fixed one-stage chi-square test. We will use the Monte Carlo simulation to 
determine if the Type I error rate is affected by various values for success probability (.1, .2, .3, 
.4 and .5) for both balanced and unbalanced cases with alpha= .01 and .05.   Likewise, we will 
use the Monte Carlo simulation to test if the power is affected by different values for success 
probabilities ((P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.4) and (P1=.4, P2=.521) ) with alpha 
=.01 for balanced and unbalanced cases and ((P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.3), 
(P1=.345, P2= .5)) and.05 for balanced and unbalanced cases.  
3.2 Monte Carlo simulation 
Monte Carlo simulations have essentially two applications. One involves their use to 
examine the empirical sampling distribution of a statistic. The theoretical distribution of a 
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statistic might be known, and so this application is designed mainly to offer an empirical demo 
of an occurrence of defined mathematical deliberations. This is a very useful application, and one 
that would seem to be very useful for teaching purposes. It is one thing to be told that some 
statistic has some characteristic sampling distribution, but it is quite another to actually see this 
sampling distribution develop.  
A second application, and perhaps an even more common one, is the use of Monte Carlo 
methods to study the effects of violating assumptions underlying some statistic. For example, we 
know that the use of the T-test to investigate a difference between two means assumes that the 
two samples were drawn at random from Normal populations. We also know in the violation of 
the normality assumption, it still appears to be okay to use the T-test. In many situations, the T-
test is relatively robust with respect to violations of the assumption of Normality; Monte Carlo 
methods were in part responsible for indicating this robustness. 
3.3 Testing Type I error 
Figure 3-1 illustrates what type of errors we have in any random clinical trial. Recall that 
the issue with the O’Brien Fleming procedure is whether the reuse of data from earlier stages 
affect the Type I error, which is located in the upper left corner of Figure 3-1, representing the 
case when we mistakenly reject the null hypothesis (mistakenly because there truly was not a 
difference between treatments). We used a Monte Carlo simulation study to test that issue, 
simulating binary data from the same binomial distribution (success probabilities (P= .1, .2, .3, 
.4, .5) to assure the null hypothesis is true) for both balanced and unbalanced cases with alpha= 
.01 and .05. For each simulated trial, we used the O’Brien Fleming procedure with the updated 
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critical values (see previous chapter), noting whether we (mistakenly) rejected the null 
hypothesis). We then repeated this process 1,000,000 times.  
3.3.1 Testing Type I error algorithm  
1. The values of the success probability (P), significant alpha (α), total sample size (N), 
number of interim analysis (K) and critical value( P (K, α)) are chosen. 
2. N/2 is the total number of subjects for each treatment in the balanced case (N in total). 
N/3 and 2N/3 are the total number of subjects for treatment1 and treatment2 respectively 
in the unbalanced case (N in total).  
3. The sample size which is needed to conduct the O’Brian Fleming is generated using the 
same binomial distribution (Binomial (P, (N/2K)) K times for both groups in the balanced 
case; Binomial (P, (N/3K)) and Binomial (P, (2N/3K)) K times in the unbalanced case) to 
make sure there is no difference between the two groups. 
4. The O’Brian Fleming test is conducted and we check if we fail to reject the Ho (that there 
is no difference) or if there is significant difference and accept the Ha (there is a 
difference between the two groups). 
5. Repeat steps two to four 1,000,000 times. Then the percentage of accepting the Ha is 
calculated. This will present the Type I error, since we are sure that there is no “true” 
difference and the method indicates that there is a difference (Figure 3-2). 
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Figure 3-2: Testing Type I error algorithm. 
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The results were reassuring: the Type I error rates were mostly less than .05 and .01, and in 
a few cases exceeded .05 and .01 (the maximums were .0534 and .0112).  This is an acceptable 
compromise considering the possible saving of time and money if the trial is terminated in earlier 
stages.  
The first simulation was for alpha=.05 with balanced sample size for K equals 1, 2, 3, 4 and 
5. The results are in the following Table (Table 3-1). We can see all the values are close to .05. 
The range for Type I error ranges between .0459 and .0534. 
Table 3-1: Type I error estimate alpha=.05 for the balanced case using Monte Carlo simulation. 
K=5 K=4 
m1 m2 P Alpha m1 m2 P Alpha 
36 36 0.1 0.0498 45 45 0.1 0.0483 
36 36 0.2 0.0501 45 45 0.2 0.0502 
36 36 0.3 0.0501 45 45 0.3 0.0499 
36 36 0.4 0.0504 45 45 0.4 0.0520 
36 36 0.5 0.0478 45 45 0.5 0.0459 
K=3 K=2 
m1 m2 P Alpha m1 m2 P Alpha 
60 60 0.1 0.0505 90 90 0.1 0.0488 
60 60 0.2 0.0506 90 90 0.2 0.0505 
60 60 0.3 0.0500 90 90 0.3 0.0501 
60 60 0.4 0.0513 90 90 0.4 0.0492 
60 60 0.5 0.0490 90 90 0.5 0.0534 
K=1 
m1 m2 P Alpha 
180 180 0.1 0.0496 
180 180 0.2 0.0506 
180 180 0.3 0.0501 
180 180 0.4 0.0487 
180 180 0.5 0.0512 
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In the second case, the simulation was for alpha=.05 with the unbalanced sample size for K 
equals 1, 2, 3, 4 and 5. We were worried that the unbalanced case would be challenging and the 
Type I error would be off. We were wrong: the Type I error is closer to .05 than it was in the 
balanced case. The range for Type I error ranges between .0480 and .0531. 
Table 3-2: Type I error estimate alpha=.05 for the unbalanced case using Monte Carlo simulation. 
K=5 K=4 
m1 m2 P Alpha m1 m2 P Alpha 
36 72 0.1 0.0499 45 90 0.1 0.0496 
36 72 0.2 0.0497 45 90 0.2 0.0499 
36 72 0.3 0.0498 45 90 0.3 0.0500 
36 72 0.4 0.0505 45 90 0.4 0.0504 
36 72 0.5 0.0499 45 90 0.5 0.0480 
K=3 K=2 
m1 m2 P Alpha m1 m2 P Alpha 
60 120 0.1 0.0490 90 180 0.1 0.0501 
60 120 0.2 0.0500 90 180 0.2 0.0498 
60 120 0.3 0.0497 90 180 0.3 0.0502 
60 120 0.4 0.0494 90 180 0.4 0.0503 
60 120 0.5 0.0531 90 180 0.5 0.0500 
K=1 
m1 m2 P Alpha 
180 360 0.1 0.0510 
180 360 0.2 0.0502 
180 360 0.3 0.0510 
180 360 0.4 0.0510 
180 360 0.5 0.0480 
 
After that, the third and the fourth simulations were conducted for alpha=.01 with balanced 
and unbalanced cases respectively (for K equals 1, 2, 3, 4 and 5). We can see for the balanced 
case (Table 3-3) all the values are close to .01. The estimates for Type I error ranges between 
.009 and .0112. Again for the unbalanced case, the Type I error is even closer to .01. The 
estimates for Type I error ranges between .0094 and .0102 (Table 3-4). Therefore, the O’Brien 
Fleming procedure works well. And we can say that the claim of O'Brien and Fleming, which 
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says that their GST procedure has the same Type I error rate and power as that of a fixed one-
stage chi-square test, is true. 
Table 3-3: Type I error estimate alpha=.01 for the balanced case using Monte Carlo simulation. 
K=5 K=4 
m1 m2 P Alpha m1 m2 P Alpha 
36 36 0.1 0.0094 45 45 0.1 0.0090 
36 36 0.2 0.0100 45 45 0.2 0.0099 
36 36 0.3 0.0100 45 45 0.3 0.0100 
36 36 0.4 0.0098 45 45 0.4 0.0099 
36 36 0.5 0.0112 45 45 0.5 0.0107 
K=3 K=2 
m1 m2 P Alpha m1 m2 P Alpha 
60 60 0.1 0.0096 90 90 0.1 0.0096 
60 60 0.2 0.0099 90 90 0.2 0.0099 
60 60 0.3 0.0099 90 90 0.3 0.0099 
60 60 0.4 0.0097 90 90 0.4 0.0100 
60 60 0.5 0.0102 90 90 0.5 0.0097 
K=1 
m1 m2 P Alpha 
180 180 0.1 0.0099 
180 180 0.2 0.0101 
180 180 0.3 0.0101 
180 180 0.4 0.0101 
180 180 0.5 0.0099 
 
Table 3-4: Type I error estimate alpha=.01 for the unbalanced case using Monte Carlo simulation. 
K=5 K=4 
m1 m2 P Alpha m1 m2 P Alpha 
36 72 0.1 0.0095 45 45 0.1 0.0100 
36 72 0.2 0.0100 45 45 0.2 0.0098 
36 72 0.3 0.0099 45 45 0.3 0.0100 
36 72 0.4 0.0099 45 45 0.4 0.0100 
36 72 0.5 0.0095 45 45 0.5 0.0105 
K=3 K=2 
m1 m2 P Alpha m1 m2 P Alpha 
60 120 0.1 0.0095 90 180 0.1 0.0094 
60 120 0.2 0.0097 90 180 0.2 0.0098 
60 120 0.3 0.0099 90 180 0.3 0.0099 
60 120 0.4 0.0100 90 180 0.4 0.0099 
60 120 0.5 0.0101 90 180 0.5 0.0097 
K=1 
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m1 m2 P Alpha3 
180 360 0.1 0.0100 
180 360 0.2 0.0101 
180 360 0.3 0.0101 
180 360 0.4 0.0102 
180 360 0.5 0.0097 
 
3.3.2 Testing the variability of simulation  
In this section we will use ANOVA to show that choosing the random seed in the Monte 
Carlo simulation does not affect the result of Type I error. We use ANOVA because we can 
consider using the Monte Carlo to calculate the Type I error as finding the mean for the output of 
the simulation (each iteration has output of 1 if we reject the null hypothesis and 0 if we failed to 
reject the null hypothesis). So the idea is to repeat the simulation process 5 times and then use 
the ANOVA to find if the means are different. 
In our case we ran five simulations for the same set of given parameters for success 
probability (P), significant alpha (α), number of interim analysis (K) and critical value( P (K, α)), 
though we used different random seeds each time. Then the output variable is the rejection 
variable (each iteration in each simulation has output of 1 if we reject the null hypothesis and 0 if 
we failed to reject the null hypothesis) and the dependent variable is the simulation number (1, 2, 
3, 4 and 5). Then the mean of each simulation is the Type1 error. For each simulation we had 
200,000 iterations (in total we had 1,000,000 which gave us the power to catch any difference 
between the iterations).  
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We ran the model and we had the following results: The model showed that there is no 
significant difference between the simulations means (F-value=1.16 and P-value =.3248). If we 
look to the means we can see they are close, ranging between .0498 and .0510. As a result we 
can say we failed to conclude that choosing the random seed in the Monte Carlo simulation will 
affect the result of Type I error. 
Table 3-5: Testing the variability model information. 
Source DF Sum of Squares Mean Square F Value Pr > F 
Model 4 0.22207 0.05552 1.16 0.3248 
Error 999995 47726.51443 0.04773     
Corrected Total 999999 47726.73650       
 
 
 
Table 3-6: Simulations means. 
Simulation no. N 
reject 
Mean Std Dev 
1 200000 0.0498 0.218 
2 200000 0.0505 0.219 
3 200000 0.0500 0.218 
4 200000 0.0498 0.217 
5 200000 0.0510 0.220 
 
3.4 Testing how the O’Brien Fleming procedure affects power 
Power is presented by the upper right corner of Figure 3-1. That presents the case where we 
reject the null hypothesis when there is a “true” difference between treatments. We are interested 
in testing power, because we want to see if increasing the number of interim analyses will 
decrease the power of the O’Brien Fleming procedure, which maybe expected because an 
increase in K increases the critical value P(K,α) which makes rejecting the null hypothesis more 
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difficult.  If that is true, we need to be cautious when we plan any studies using the O’Brien 
Fleming procedure. So we again used a Monte Carlo simulation to test the power, simulating 
binary data from different binomial distributions with different success probabilities ((P1=.3, 
P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.4) and (P1=.4, P2=.521)  with alpha =.01 for balanced and 
unbalanced cases and (P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.3), (P1=.345, P2= .5) and .05 
for balanced and unbalanced cases) to assure the null hypothesis is not true. For each simulated 
trial, we used the O’Brien Fleming procedure with the updated critical values, noting whether we 
rejected the null hypothesis. We then repeated this process 1,000,000 times, and use the 
percentage of the times we rejected the null hypothesis as an estimated power since we are sure 
that there is a “true” difference. 
 
3.4.1 Testing power algorithm  
1. The values of the success probabilities (P1, P2), significant alpha (α), total sample size 
(N), number of interim analysis (K) and critical value (P (K, α)) are chosen. 
2. Power for N doing the ordinary chi-square test is calculated using nQuery for the use of 
comparison.  
3. N/2 is the total number of subjects for each treatment in the balanced case (N in total). 
N/3 and 2N/3 are the total number of subjects for treatment1 and treatment2 respectively 
in the unbalanced case (N in total).   
4. The sample size which is needed to conduct the O’Brian Fleming is generated using the 
binomial distribution (Binomial (P1, (N/2K)) for the first group and Binomial (P2, 
(N/2K)) for the second group K times in the balanced case; Binomial (P1, (N/3K)) for the 
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first group and Binomial (P2, (2N/3K)) for the second group K times in the unbalanced 
case) to assure that there is a difference between the two groups. 
5. The O’Brian Fleming test is conducted and we check whether we fail to reject the Ho 
(that there is no difference) or accept the Ha which indicates that there is a significant 
difference. 
6. Repeat steps two to five 1,000,000 times, then the percentage of accepting the Ha is 
calculated (which represents power) since we are sure that there is a difference and the 
method indicates that there is a difference (Figure 3-3). 
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Figure 3-3: Testing power algorithm. 
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We chose P1=.3, P2=.4, (α=.05 or .01) and (m1, m2) = (180/K, 180/K) in balanced case 
(360 in total) and m1=180/K, m2=360/K in unbalanced case (540 in total). We used nQuery to 
calculate the power needed for the ordinary chi-square using each case of the four cases. For the 
first case, when alpha equals .05 with balanced samples (n1=180 and n2=180) the power is 51%. 
In the result for the O’Brien Fleming procedure using the Monte Carlo simulation, the power 
ranges from 0.500 to .516 (Table 3-9). The second case when alpha equals .01 with balanced 
samples (n1=180 and n2=180) the power is 27%. In the result for the O’Brien Fleming procedure 
the power ranges from 0.273 to .280 (Table 3-9). For the unbalanced case (n1=180 and n2=360). 
The power for alpha equals .05 is 58% compared to the O’Brien Fleming procedure power which 
ranges from 0.614 to 0.628 (Table 3-9). And for alpha .01 the power is 34% compared to the 
O’Brien Fleming procedure power which ranges from 0.371 to 0.379 (Table 3-9). 
Table 3-7: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 0.050 0.010 
          Group 1 proportion, p1 0.300 0.300 0.300 0.300 
          Group 2 proportion, p2 0.400 0.400 0.400 0.400 
      n1 180 180 180 180 
      n2 180 180 360 360 
  N=n1 + n2 360 360 540 540 
  Power  51% 27% 58% 34% 
 
Table 3-8: Power estimates using Monte Carlo simulation for different cases. 
 
 
 
  
 
 
alpha m1 m2 P1-P2   
power 
K=1 K=2 K=3 K=4 K=5 iterations 
.01 180 180 0.3-0.4 0.27908 0.27737 0.27621 0.27665 0.27303 1000000 
.05 180 180 0.3-0.4 0.51551 0.50980 0.50155 0.50091 0.50076 1000000 
.01 180 360 0.3-0.4 0.37895 0.37901 0.37604 0.37563 0.37065 1000000 
.05 180 360 0.3-0.4 0.62809 0.62334 0.61945 0.61546 0.61382 1000000 
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Moreover, we wanted to test the O’Brien Fleming procedure for higher power. So we 
tested for four extra scenarios. First scenario, P1=.2, P2=.3, α=.05 and (m1, m2) = (300/K, 
300/K). We used nQuery to calculate the power needed for the ordinary chi-square using. Power 
equals 80% for the setup of P1=.2, P2=.3, α=.05 and n= 300 per group. In the result for the 
O’Brien Fleming procedure using the Monte Carlo simulation, the power ranges from 0.799 to 
.811 (Table 3-11). Second scenario, P1=.2, P2=.4, α=.01 and (m1, m2) = (120/K, 120/K). We 
calculated the power using the nQuery, power equals %79 for the setup of P1=.2, P2=.4, α=.01 
and n= 120 per group. The power ranges from 0.794 to .803 (Table 3-11) for the O’Brien 
Fleming procedure using the Monte Carlo simulation. Third scenario, P1=.345, P2=.5, α=.05 and 
(m1, m2) = (120/K, 240/K). The nQuery resulted power equals %84 for the setup of P1=.345, 
P2=.5, α=.05 and (n1, n2) = (120/K, 240/K). The power ranges from 0.838 to .848 (Table 3-11) 
using the Monte Carlo simulation results for the O’Brien Fleming procedure. For the last 
scenario, P1=.4, P2=.521, α=.01 and (m1, m2) = (300/K, 600/K). Power equals %80 for the setup 
of P1=.4, P2=.521, α=.01 and (n1, n2) = (300/K, 600/K) using the nQuery. Once more, the power 
ranges from 0.799 to .806 from the Monte Carlo simulation for the O’Brien Fleming procedure 
(Table 3-11). 
Table 3-9: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 0.050 0.010 
          Group 1 proportion, p1 0.200 0.200 0.345 0.400 
          Group 2 proportion, p2 0.300 0.400 0.500 0.521 
      n1 300 120 120 300 
      n2 300 120 240 600 
  N=n1 + n2 600 240 360 900 
  Power  %80 %79 %84 %80 
 
 
 
Table 3-10: Power estimates using Monte Carlo simulation for different cases. 
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After using Monte Carlo to calculate the power for the eight cases, we had interesting 
results (Table 3-9 and Table 3-11). First, as we know when K equals one in the O’Brien Fleming 
Procedure is actually the traditional chi-square test. So if we compare the power when K equals 
one and the nQuery, the nQuery obviously underestimated the power especially in the 
unbalanced case. Second, as we expected when the number of interim analysis increases the 
power decreases. It is clear that the differences between the powers in each case are so small that 
it can be overlooked. Also most powers are higher than the estimates from nQuery so we are 
always on the safe side. That because nQuery most likely will overestimate the sample size 
needed for any study. That being said, we can conclude that increasing the number of interim 
analyses of the O’Brien Fleming will decrease the power slightly. So we have the choice to pick 
the number of interim analyses that suits any study’s needs.      
3.5 Conclusions  
In this chapter we examined whether the O’Brien Fleming procedure maintains the desired 
Type I error rate, since it reuses data from earlier stages and maintains the sample size for the 
desired power. We used Monte Carlo simulation to examine the Type I error and the power for 
the O’Brien Fleming procedure for different scenarios. For the Type I error, the O’Brien Fleming 
procedure works well. And we can say that the claim of O'Brien and Fleming, which says that 
alpha m1 m2 P1-P2   
power 
K=1 K=2 K=3 K=4 K=5 iterations 
.05 300 300 0.2-0.3 0.81084 0.80750 0.80306 0.80077 0.79977 1000000 
.01 120 120 0.2-.04 0.80247 0.79661 0.79651 0.79505 0.79412 1000000 
.05 120 240 0.345-0.5 0.84791 0.84445 0.84187 0.83941 0.83772 1000000 
.01 300 600 0.4-.0521 0.80645 0.80748 0.80019 0.79782 0.79890 1000000 
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their GST procedure has the same Type I error rate and power as that of a fixed one-stage chi-
square test, is true. For the power, when the number of interim analysis for the O’Brien Fleming 
procedure increases the power decreases. On the other hand, the effect of increasing the number 
of interim analysis is so small that it can be overlooked. Overall the O’Brien Fleming procedure 
works as well as the usual chi-square test. 
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Chapter 4 : Extending the O’Brien Fleming procedure 
 
 4.1 Introduction 
In the previous two chapters we explained, illustrated, corrected and tested the O’Brien 
Fleming GST procedure. In the second chapter we explained the O’Brien Fleming GST 
procedure, and discussed it’s the theoretical background for the procedure. Then we noticed the 
stopping bounds for the O’Brien Fleming GST procedure are off. We used O’Brien and Fleming 
simulations to generate the new bounds with using a larger number of iterations than the original 
authors. Then we stated two examples to illustrate how the procedure works when there is a 
significant difference or when there is not a significant difference. In the third chapter we 
verified the O’Brien Fleming GST procedure. By testing the Type I error and power. For the 
Type I error we confirmed the claim of O'Brien and Fleming which says that their GST 
procedure has the same Type I error rate and power as that of a fixed one-stage chi-square test . 
For power, we concluded that increase the number of interim analyses of the O’Brien Fleming 
GST procedure will decrease the power slightly, which can be over looked. So we presented in 
the previous two chapters how the O’Brien Fleming GST procedure is a trusted straightforward 
procedure.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
In this chapter we are going to extend the O’Brien Fleming GST procedure in three ways. 
The first extension will be combining the O’Brien Fleming GST procedure with the optimal 
allocation. After each stage in the O’Brien Fleming GST procedure we calculate the new 
allocation ratio for both groups depending on the optimality criteria using the success counts for 
the two groups from the previous stage, so the allocation may change from stage to stage through 
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the study. The idea behind the optimal allocation is to allocate more patients to the better 
treatment. The second extension will be combining the O’Brien Fleming GST procedure with the 
Neyman allocation. After each stage in the O’Brien Fleming GST procedure we calculate the 
new allocation ratio for both groups depending on the Neyman criteria using the success and 
failure counts for the two groups from the previous stage. So the allocation also may change 
from stage to stage through the study. The idea behind Neyman allocation is to minimize the 
variance of the difference in sample proportions. The last extension involves changing the 
sample size from stage to stage in the procedure. In the original O’Brien Fleming GST procedure 
we are supposed to choose the same sample size for all stages. As done in the previous chapter, 
we will test the Type I error and power for each extension. To check if the procedure is affected 
by any extension we do, we are using all the scenarios we used in the previous chapter for testing 
the Type I error.  
4.2 Extending the O’Brien Fleming Multiple procedure using the optimal allocation  
4.2.1 The optimal allocation 
Let f (PA, PB) be a function to compare two binomial probabilities. Three usually used 
functions are the simple difference=PA - PB, the relative risk=pB/pA and the odds 
ratio=PAqB/PBqA. We estimate these functions by replacing PA by   ̂ and PB by   ̂, where   ̂ and 
  ̂  are the proportions of successes we observe for group A and group B respectively. We can 
use the delta method to estimate the asymptotic variances of these estimators avar {f ((PA, PB)}. 
The idea is to find the optimal allocation R=nA/nB that has a fixed asymptotic variance to 
minimize the expected number of failures by allocating the patients to the better treatment.   
The optimal allocation is determined by the unknown binomial parameters, Rosenberger 
Stallard, Ivanova, Harper and Ricks
30
 needed to develop a sequential design to estimate the 
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optimal design. Let X1, . . ., Xn be a binary response (with two values success=1 and failure=0), 
and T1, . . . , Tn are treatment assignment indicators, which have the values one for treatment A 
and zero for treatment B. Then they wrote NA,n=∑   
 
    , NB,n=n-NA,n,   ̂   ∑         
 
   , 
  ̂   ∑             
 
   ,  ̂       ̂   and  ̂       ̂  . then, they denoted Fi={ 
X1, . . . , Xi , T1, . . . , Ti } and conditional expectation as Ei(۰)=E(۰|Fi ). They stated the 
following allocation rule:  
         
√ ̂     
√ ̂      √ ̂     
 
Therefore, this rule simply substitutes the unknown success probabilities in the optimal 
allocation rule by the existing estimate of the proportion of successes on each treatment thus far 
in the trial. When PA, PB   (0, 1),  
   
 
  √
  
√   √  
  as n   ,  
Then they reached that the following formula  
√  
√   √  
   is the optimal allocation. 
4.2.2 The O’Brien Fleming Optimal Allocation GST procedure 
This GST procedure can be used in any clinical trial which compares two treatments with 
binary outcomes. The data must be collected independently on each treatment. 
The procedure is as follows: the data are reviewed and tested periodically with n subjects 
/stage receiving treatment 1 and treatment 2. The allocation will be an equal allocation in the first 
stage, and then it will start to change using the optimal allocation rule. Since there are K tests, 
the maximum number of subjects is     ; K and n are fixed in advance.  
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1. First, n1 and n2 subjects are assigned to treatments 1 and 2, respectively (n1and n2 
must be equal and n=n1+n2). The experiment is terminated and the hypothesis of no 
difference between treatments rejected if       
2
1
l /   P ,  ,K K   where  
2
1
  is the 
usual Pearson chi-square statistic, α is the size of the test, and P (K, α) is a critical 
value obtained from an O’Brian Fleming Table 2-1.  
2. Otherwise, if the critical value is not exceeded, we recalculate the next n1 and n2 as 
follows: 
       , where    
√  
√   √  
 and          
subjects are randomized and their measurements are observed.  
3. In general, for the kth test the study is terminated and the null hypothesis is rejected if 
     
2   P ,  ,
k
k / K K   where  
2
k
  is the usual Pearson chi-square statistic based 
on all data collected up to the kth test. If not we repeat steps two and three. 
4.  If after completing K tests
 
2
K
  does not exceed  P ,  K  , the study is terminated 
with the conclusion that the hypothesis of no difference cannot be rejected at α level 
of significance.  
 
4.2.3 The O’Brien Fleming Optimal Allocation GST procedure illustrating 
examples   
      In this section we will provide two examples to demonstrate how the O’Brien Fleming 
Optimal Allocation GST procedure works when there is a significant difference or insignificant 
difference. For illustration when there is a significant difference between the groups, we used 
simulated data for 60 subjects for each group (120 total subjects with P1=.3 and P2=.4), then we 
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used the O’Brien Fleming procedure with the optimal allocation for different number of interim 
analysis (K=1, 2, 3, 4 and 5), and specified which case required the fewest subjects. 
 Case 1: n=120, K=1. 
 Case 2: n=60, K=2. 
 Case 3: n=40, K=3. 
 Case 4: n=30, K=4. 
 Case 5: n=24, K=5. 
For the first case K=1 and n1=n2=60, so we used P (K=1, α=.05)=3.84. We used all of the 
sample size at once. Then we used the GST procedure (that is the same as chi-square when K=1) 
The O’Brien Fleming test statistic is equal 5.647 which is greater than 3.84. So the statistic for 
this interim analysis was significant, indicating a difference between the treatments (Table 4-1). 
Table 4-1: Case 1 result for the O’Brien Fleming Optimal Allocation GST procedure. 
Case1 analysis results. 
k alpha n1
* 
n2
*
 X1
**
 X2
**
 Total Sample size (k/K)Chi-square 
1 3.84 60 60 22 35 120 5.647 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
For the second case, we divided the sample size into two equal clusters, so K=2, n=60 and 
we used P (K=2, α=.05)=3.92. Then we used the GST procedure with optimal allocation but we 
could not terminate the trial in the first interim analysis, because the statistic did not exceed the P 
(K=2, α=.05) (statistic equals 1.649 which is less than 3.92). Therefore we had to use the entire 
sample size of 60 for each group. We used the success rate in the first stage to recalculate n1 and 
n2: 
   
√    
√     √    
        then                 
 
 
45 
 
so the cumulated sample size for the first group in the second stage is n12=57 and the cumulated 
sample size for the second group in the second stage is n22=63. The statistic for the second 
interim analysis was also significant. The O’Brien Fleming test statistic is equal 5.848 which is 
greater than 3.92, indicating a difference between the treatments (Table 4-2). 
Table 4-2: Case 2 result the O’Brien Fleming Optimal Allocation GST procedure. 
Case2 analysis results. 
k alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 3.92 30 30 13 20 60 1.649 
2 3.92 57 63 20 36 120 5.848 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
In the third case, we divided the sample size into three equal clusters, and then we used the 
GST procedure with K=3, n=40 and P (K=3, α=.05)=4.02. We failed to reject the Ho in the first 
two stages. And we recalculated n1 and n2 after each stage. After the first stage, the cumulated 
sample size for the first group in the second stage is                            
       and the cumulated sample size for the second group in the second stage is       . 
After the second stage we recalculate the sample size again. The cumulated sample size for the 
first group in the third stage is                                   and the 
cumulated sample size for the second group in the third stage is        .The statistic exceeded 
the cutoff (which equals 4.02) in the third interim analysis (the test statistic equals 9.427). So the 
trial was terminated using all the subjects to conclude that there is a significant difference 
between the two treatments (Table 4-3). 
Table 4-3: Case 3 result the O’Brien Fleming Optimal Allocation GST procedure. 
Case3 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 4.02 20 20 2 11 40 3.077 
2 4.02 32 48 9 25 80 3.007 
3 4.02 49 71 10 34 120 9.427 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
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In the fourth case, we divided the sample size into four equal clusters, and then we used the 
GST procedure with K=4, n=30 and P (K=4, α=.05)=4.16. We failed to reject the Ho in the first 
two stages, and we recalculated n1 and n2 after each stage. After the first stage, the cumulated 
sample size for the first group in the second stage is                            
      and the cumulated sample size for the second group in the second stage is       . 
After the second stage we recalculate the sample size again. The cumulated sample size for the 
first group in the third stage is                                   and the 
cumulated sample size for the second group in the third stage is           The statistic 
exceeded the cutoff (which equals 4.16) in the third interim analysis (the test statistic equals 
6.355). So the trial was terminated using 90 subjects to conclude that there is a significant 
difference between the two treatments (Table 4-4). 
Table 4-4: Case 4 result the O’Brien Fleming Optimal Allocation GST procedure. 
Case4 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi-square 
1 4.10 15 15 1 8 30 1.944 
2 4.10 23 37 6 19 60 1.862 
3 4.10 35 55 6 26 90 6.355 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
For the fifth case, we divided the sample size into five equal clusters. We used the GST 
procedure with K=5, n=24 and P (K=5, α=.05)=4.16. We failed to reject the Ho in the first three 
stages, and we recalculated n1 and n2 after each stage. After the first stage, the cumulated sample 
size for the first group in the second stage is                                  
and the cumulated sample size for the second group in the second stage is       . After the 
second stage we recalculate the sample size again. the cumulated sample size for the first group 
in the third stage is                                   and the cumulated 
sample size for the second group in the third stage is          Then after recalculating n1 and 
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n2 for the fourth stage, the cumulated sample size for the first group in the third stage is     
                              and the cumulated sample size for the second group 
in the third stage is          The statistic exceeded the cutoff (which equals 4.16) in the fourth 
interim analysis (the test statistic equals 9.605). So the trial was terminated using 96 subjects to 
conclude that there is a significant difference between the two treatments (Table 4-5). 
Table 4-5: Case 5 result the O’Brien Fleming Optimal Allocation GST procedure. 
Case5 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 4.16 12 12 2 4 24 0.177 
2 4.16 22 26 4 11 48 1.291 
3 4.16 32 40 7 17 72 2.041 
4 4.16 42 54 7 25 96 9.605 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
 
As we can see, the fourth case found there was a difference with just 90 subjects in total, 
which is less than the 120 subjects that would have been used in a conventional clinical trial. The 
following example is to illustrate how the procedure works when there is no difference between 
the two treatments. We simulated the two groups from the same distribution to make sure that 
there is no difference between the means. So we have data for 60 subjects for each group that 
have been simulated from binomial distribution with P=.4 (120 total subjects). We used the 
O’Brien Fleming GST procedure for different numbers of interim analysis (K=1, 2, 3, 4 and 5). 
Again we used: 
 Case 1: n=120, K=1. 
 Case 2: n=60, K=2. 
 Case 3: n=40, K=3. 
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 Case 4: n=30, K=4. 
 Case 5: n=24, K=5. 
For all interim analysis in all cases we failed to find a difference (which is expected); all 
(k/K) Chi-square values are less than the alpha values (Table 4-6). The allocation between the 
groups stayed almost equal. This is caused by success rates was generated from the same 
distribution, so most of the time they will be equal, so   
√  
√   √  
=.5 most of the time. 
Table 4-6: The second example results. 
Case1 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total Sample size (k/K)Chi-square 
1 3.84 26/60 23/60 120 0.0345 
Case2 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 3.92 11/30 9/30 60 0.1500 
2 3.92 22/62 20/58 120 0.0132 
Case3 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 4.02 7/20 6/20 40 0.0380 
2 4.02 14/41 13/39 80 0.0039 
3 4.02 23/61 22/59 120 0.0022 
Case4 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 4.10 5/15 4/15 30 0.0317 
2 4.10 10/31 9/29 60 0.0041 
3 4.10 17/46 15/44 90 0.0604 
4 4.10 21/61 21/59 120 0.0143 
Case5 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 4.16 4/12 3/12 24 0.0403 
2 4.16 8/25 7/23 48 0.0055 
3 4.16 13/37 12/35 72 0.0034 
4 4.16 16/49 17/47 96 0.1052 
5 4.16 22/61 24/59 120 0.2699 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
4.2.4 Testing Type I error 
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Recall that the issue with any interim analysis is whether the reuse of data from earlier 
stages affect the Type I error. So for the O’Brien Fleming Optimal Allocation GST procedure we 
are worried about the Type I error because the allocation favors the better treatment whether its 
truly better or not. This may cause a false significant difference, which leads to a higher Type I 
error. Again we used a Monte Carlo simulation study to test the Type I error for the O’Brien 
Fleming Optimal Allocation GST procedure (simulating binary data from the same binomial 
distribution with success probabilities (P=.1, .2, .3, .4, .5) with alpha=.01 and .05 to assure the 
null hypothesis is true) for each simulated trial, noting whether we (mistakenly) rejected the null 
hypothesis. We then repeated this process 1,000,000 times and calculated the percentage of 
rejecting the null hypothesis.  
4.2.4.1 Testing Type I error algorithm  
1. The values of the success probability (P), significant alpha (α), total sample size (N), 
number of interim analysis (K) and P (K, α) are chosen. 
2. n=N/K is the total number of subjects for each stage. For the first stage we start with the 
balanced case (N in total).  
3. The sample size needed for the first stage is generated using the same binomial 
distribution (Binomial (P, (N/2K)) Then using the success rates (P1 and P2) to recalculate 
the new allocation and generate the sample for the following stage, we do the allocation 
recalculation K-1 times using the cumulative success rates.  
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4. The O’Brian Fleming test is conducted and checked if we fail to reject the Ho (that there 
is no difference) or there is significant difference and accept the Ha (there is a difference 
between the two groups). 
5. Repeat this 1,000,000 times, then the percentage of accepting the Ha is calculated. This 
will present the Type I error, since we are sure that there is no difference, even though the 
method indicates that there is a difference (Figure 4-1). 
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Figure 4-1: Testing Type I error algorithm for the O’Brien Fleming Optimal Allocation GST procedure. 
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The results were encouraging: the Type I error rates were mostly less than .05 and .01, and 
in a few cases exceeded .05 and .01 (the maximums were .0519 and .0103).  These results for the 
Type I error are more accurate than that for the original O’Brien Fleming GST procedure.  
The first simulation was for alpha=.05 starting with a balanced sample size for K=1, 2, 3, 4 
and 5 and (P1= P2=.1, .2, .3, .4 and .5). The results are in the following Table (Table 4-7). We 
can see all the values are close to .05. The values for Type I error values are between .0459 and 
.0519. 
Table 4-7: Type I estimate for alpha=.05 for the O’Brien Fleming Optimal Allocation GST procedure. 
K=5 K=4 
n P1=P2 Alpha n P1=P2 Alpha 
72 0.1 0.0459 90 0.1 0.0487 
72 0.2 0.0504 90 0.2 0.0502 
72 0.3 0.0506 90 0.3 0.0503 
72 0.4 0.0485 90 0.4 0.0503 
72 0.5 0.0510 90 0.5 0.0519 
K=3 K=2 
n P1=P2 Alpha n P1=P2 Alpha 
120 0.1 0.0492 180 0.1 0.0487 
120 0.2 0.0506 180 0.2 0.0501 
120 0.3 0.0502 180 0.3 0.0508 
120 0.4 0.0506 180 0.4 0.0508 
120 0.5 0.0500 180 0.5 0.0500 
K=1 
n P1=P2 Alpha 
360 0.1 0.0486 
360 0.2 0.0507 
360 0.3 0.0509 
360 0.4 0.0508 
360 0.5 0.0505 
 
 
After that, the second simulations were conducted for alpha=.01 for K equals 1, 2, 3, 4 and 
5. All the values are close to .01. The values for Type I error values for the balanced case are 
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between .009 and .0112 (Table 4-8). Therefore, the O’Brien Fleming Optimal Allocation 
procedure works well. And we can say that the O'Brien Fleming Optimal Allocation procedure 
has the same Type I error rate as that of a fixed one-stage chi-square. 
 
Table 4-8: Type I estimate for alpha=.01 the O’Brien Fleming Optimal Allocation GST procedure. 
K=5 K=4 
n P1=P2 Alpha n P1=P2 Alpha 
72 0.1 0.0098 90 0.1 0.0090 
72 0.2 0.0100 90 0.2 0.0098 
72 0.3 0.0100 90 0.3 0.0101 
72 0.4 0.0100 90 0.4 0.0101 
72 0.5 0.0098 90 0.5 0.0101 
K=3 K=2 
n P1=P2 Alpha n P1=P2 Alpha 
120 0.1 0.0084 180 0.1 0.0080 
120 0.2 0.0096 180 0.2 0.0098 
120 0.3 0.0099 180 0.3 0.0099 
120 0.4 0.0101 180 0.4 0.0100 
120 0.5 0.0103 180 0.5 0.0100 
K=1 
n P1=P2 Alpha 
360 0.1 0.0079 
360 0.2 0.0100 
360 0.3 0.0098 
360 0.4 0.0099 
360 0.5 0.0101 
 
4.2.5 Testing how the O’Brien Fleming Optimal Allocation GST procedure 
affects power 
We used Monte Carlo simulations to test the power as we did before with original O’Brien 
Fleming GST procedure in Chapter Three. Power presents the case where we reject the null 
hypothesis when there is a “true” difference between treatments. We are interested in testing 
power again, because we want to see if changing the allocation will decrease the power of the 
original O’Brien Fleming procedure. We simulated binary data from different binomial 
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distribution with different success probabilities ((P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.4) 
and (P1=.4, P2=.521)  with alpha=.01 and (P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.3), 
(P1=.345, P2=.5) and alpha=.05) to assure the null hypothesis is not true. For each simulated 
trial, we used the O’Brien Fleming Optimal Allocation procedure with the updated critical 
values, noting whether we rejected the null hypothesis. We then repeated this process 1,000,000 
times, and use the percentage of the times we rejected the null hypothesis as an estimated power 
since we are sure that there is a “true” difference. 
4.2.5.1 Testing power algorithm  
1. The values of the success probabilities (P1, P2), significant alpha (α), total sample size 
(N), number of interim analysis (K) and critical value (P (K, α)) are chosen. 
2. Power for N doing the ordinary chi-square test is calculated using nQuery for the use of 
comparison.  
3. n=N/K is the total number of subjects for each stage. For the first stage we start with the 
balanced case (N in total).    
4. The sample size needed for the first stage is generated using the binomial distributions 
(Binomial (P1, (N/2K) and Binomial (P2, (N/2K))) Then using the success rates ( ̂ and 
 ̂ ) to recalculate the new allocation and generate the sample for the following stage, we 
do the allocation recalculation K-1 times using the cumulative success rates.  
5. The O’Brian Fleming Optimal Allocation test is conducted and we check whether we fail 
to reject the Ho (that there is no difference) or accept the Ha which indicates that there is 
a significant difference. 
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6. Repeat steps two to five 1,000,000 times, then the percentage of accepting the Ha is 
calculated (which represents power) since we are sure that there is a difference and the 
method indicates that there is a difference (Figure 4-2). 
 
Figure 4-2: Testing power algorithm for the O’Brian Fleming Optimal Allocation procedure. 
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We chose P1=.3, P2=.4, (α=.05 or .01) and n=(360/K) in balanced case (360 in total) We 
used nQuery to calculate the power needed for the ordinary chi-square for the two cases. For the 
first case, when alpha equals .05 with balanced samples (n1=180 and n2=180) the power is 51%. 
In the result for the O’Brien Fleming Optimal Allocation procedure using the Monte Carlo 
simulation, the power values are from 0.499 to .517 (Table 4-10).The second case when alpha 
equals .01 with balanced samples (n1=180 and n2=180) the power is 27%. The O’Brien Fleming 
Optimal Allocation procedure lead to the power values are from 0.269 to .280 (Table 4-10). 
Table 4-9: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 
          Group 1 proportion, p1 0.300 0.300 
          Group 2 proportion, p2 0.400 0.400 
      n1 180 180 
      n2 180 180 
  N=n1 + n2 360 360 
  Power  51% 27% 
 
Table 4-10: Power estimates using Monte Carlo simulation for different cases for the O’Brien Fleming Optimal Allocation GST 
procedure. 
 
 
 
Moreover, we wanted to test the O’Brien Fleming Optimal Allocation procedure for higher 
power. So we tested for two extra scenarios. First scenario P1=.2, P2=.3, α=.05 and (n=600/K). 
alpha Total n1 Total n2 P1-P2 
power 
K=1 K=2 K=3 K=4 K=5 iterations 
.01 180 180 0.3-0.4 0.280 0.277 0.274 0.272 0.269 1000000 
.05 180 180 0.3-0.4 0.517 0.508 0.504 0.500 0.499 1000000 
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We used nQuery to calculate the power needed for the ordinary chi-square using. Power equals 
80% for the setup of P1=.2, P2=.3, α=.05 and ni=300 per group. In the result for the O’Brien 
Fleming Optimal Allocation procedure using the Monte Carlo simulation, the power values are 
from 0.797 to .811 (Table 4-12). Second scenario P1=.2, P2=.4, α=.01 and (n=240/K). We 
calculated the power using the nQuery. Power equals 79% for the setup of P1=.2, P2=.4, α=.01 
and n=120 per group. For the O’Brien Fleming Optimal Allocation procedure using the Monte 
Carlo simulation the power values are from 0.779 to .802 (Table 4-12).  
Table 4-11: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 
          Group 1 proportion, p1 0.200 0.200 
          Group 2 proportion, p2 0.300 0.400 
      n1 300 120 
      n2 300 120 
  N=n1 + n2 600 240 
  Power  80% 79% 
 
Table 4-12: Power estimates using Monte Carlo simulation for different cases. 
 
 
 
 
 
After using Monte Carlo to calculate the power for the four cases, we had interesting 
results (Table 4-10 and Table 4-12). As we expected when the number of interim analysis 
increases, the power decreases. It is clear that the differences between the powers in each case 
are small that it can be overlooked. Also some empirical powers are higher than the estimates 
from nQuery. And we have the choice to pick the number of interim analyses that suits a study’s 
needs.      
alpha Total n1 Total n2 P1-P2 
power 
K=1 K=2 K=3 K=4 K=5 iterations 
.05 300 300 0.2-0.3 0.811 0.806 0.802 0.799 0.797 1000000 
.01 120 120 0.2-.04 0.802 0.796 0.788 0.784 0.779 1000000 
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4.3 Extending the O’Brien Fleming Multiple procedure using the Neyman allocation  
4.3.1 The Neyman allocation 
The Neyman allocation is determined by the unknown binomial parameters, Rosenberger 
Stallard, Ivanova, Harper and Ricks
30 
needed to develop a sequential design to estimate the 
Neyman design. Let X1, . . . Xn be a binary response (with two values success=1 and  failure=0) 
And T1, . . . , Tn are treatment assignment indicators, which have the value one for treatment A 
and zero for treatment B. Then they wrote NA,n=∑   
 
    , NB,n=n-NA,n,   ̂   ∑         
 
   , 
  ̂   ∑             
 
   ,  ̂       ̂   and  ̂       ̂  . Denoting Fi={ X1, . . . , Xi 
, T1, . . . , Ti } and conditional expectation as Ei(۰)=E(۰|Fi ), they  stated the following allocation 
rule:  
         
√ ̂      ̂     
√ ̂      ̂      √ ̂      ̂     
 
Therefore, this rule simply substitutes the unknown success and failures probabilities in the 
Neyman allocation rule by the existing estimate of the proportion of successes and failures on 
each treatment thus far in the trial. When               (0, 1),  
   
 
  √
    
√     √    
  as n   ,  
Then they reached that the following formula  
√    
√     √    
   is the Neyman allocation. 
4.3.2 The O’Brien Fleming Neyman Allocation GST procedure 
This GST procedure can be used in any clinical trial which compares two treatments with 
binary outcomes. The data must be collected independently on each treatment. 
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The procedure is as follows: the data are reviewed and tested periodically with n 
subjects/stage receiving treatment 1 and treatment 2. The allocation will be an equal allocation in 
the first stage, and then it will start to change using the optimal allocation rule. Since there are K 
tests, the maximum number of subjects is      ; K and n are fixed in advance.  
1. First, n1 and n2 subjects are assigned to treatments 1 and 2, respectively (n1and n2 
must be equal and n=n1+n2). The experiment is terminated and the hypothesis of no 
difference between treatments rejected if       
2
1
l /   P ,  ,K K   where  
2
1
  is the 
usual Pearson chi-square statistic, α is the size of the test, and P (K, α) is a critical 
value obtained from an O’Brian Fleming Table 2.1.  
2. Otherwise, if the critical value is not exceeded, we recalculate the next n1 and n2 as 
follows: 
       , where   
√    
√     √    
 and          
subjects are randomized and their measurements are observed.  
3. In general, for the kth test the study is terminated and the null hypothesis is rejected if 
     
2   P ,  ,
k
k / K K   where  
2
k
  is the usual Pearson chi-square statistic based 
on all data collected up to the kth test. If not we repeat steps two and three. 
4. If after completing K tests
 
2
K
  does not exceed  P ,  K  , the study is terminated 
with the conclusion that the hypothesis of no difference cannot be rejected at α level 
of significance.  
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4.3.3 The O’Brien Fleming Neyman Allocation GST procedure illustrating 
examples   
      In this section we provide two examples to demonstrate how the O’Brien Fleming Neyman 
Allocation GST procedure works when there is a significant difference or insignificant 
difference. For illustration when there is a significant difference between the groups, we used a 
simulated data for 60 subjects for each group (120 total subjects with P1=.3 and P2=.4), then we 
used the O’Brien Fleming procedure with the Neyman allocation for different number of interim 
analysis (K=1, 2, 3, 4 and 5), and specified which case required the fewest subjects. 
 Case 1: n=120, K=1. 
 Case 2: n=60, K=2. 
 Case 3: n=40, K=3. 
 Case 4: n=30, K=4. 
 Case 5: n=24, K=5. 
For the first case K=1 and n1=n2=60, so we used P (K=1, α=.05)=3.84. We used all of the sample 
size at once. Then we used the GST procedure (that is the same as chi-square when K=1) The 
O’Brien Fleming test statistic is equal 8.46 which is greater than 3.84. So the statistic for this 
interim analysis was significant, indicating a difference between the treatments (Table 4-13). 
Table 4-13: Case 1 result for The O’Brien Fleming Neyman Allocation GST procedure. 
Case1 analysis results. 
k alpha n1
*
 n2
*
 X1
**
 X2
**
 Total Sample size (k/K)Chi-square 
1 3.84 60 60 12 27 120 8.457 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
For the second case, we divided the sample size into two equal clusters, so K=2, n=60 and we 
used P (K=2, α=.05)=3.92. Then we used the GST procedure with optimal allocation but we 
could not terminate the trial in the first interim analysis, because the statistic did not exceed the P 
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(K=2, α=.05) (statistic equals 0.369 which is less than 3.92). Therefore we had to use the entire 
sample size of 60 for each group. We used the success rate in the first stage to recalculate n1 and 
n2: 
   
√           
√            √           
        then                           
so the cumulated sample size for the first group in the second stage is n12=58 and the cumulated 
sample size for the second group in the second stage is n22=62. The statistic for the second 
interim analysis was significant. The O’Brien Fleming test statistic is equal 4.271 that is greater 
than 3.92, indicating a significant difference between the treatments (Table 4-14). 
Table 4-14: Case 2 result for The O’Brien Fleming Neyman Allocation GST procedure. 
Case2 analysis results. 
k alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 3.92 30 30 7 10 60 0.369 
2 3.92 58 62 14 26 120 4.271 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
 
In the third case, we divided the sample size into three equal clusters, and then we used the 
GST procedure with K=3, n=40 and P (K=3, α=.05)=4.02. We failed to reject the Ho in the first 
stage. And we recalculated n1 and n2 after the first stage. The cumulated sample size for the first 
group in the second stage is                                   and the 
cumulated sample size for the second group in the second stage is        . The statistic 
exceeded the cutoff (which equals 4.02) in the second interim analysis (the test statistic equals 
4.502). So the trial was terminated with using 80 subjects to conclude that there is a significant 
difference between the two treatments (Table 4-15). 
Table 4-15: Case 3 result for The O’Brien Fleming Neyman Allocation GST procedure. 
Case3 analysis results. 
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K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 4.02 20 20 5 7 40 0.158 
2 4.02 39 41 9 21 80 4.502 
*these are the cumulated sample sizes.**X1  and X2 are success counts. 
 
In the fourth case, we divided the sample size into four equal clusters, and then we used the 
GST procedure with K=4, n=30 and P (K=4, α=.05)=4.16. We failed to reject the Ho in the first 
three stages, and we recalculated n1 and n2 after each stage. After the first stage, the cumulated 
sample size for the first group in the second stage is                            
      and the cumulated sample size for the second group in the second stage is       . 
After the second stage we recalculate the sample size again, and The cumulated sample size for 
the first group in the third stage is                                   and the 
cumulated sample size for the second group in the third stage is           The cumulated 
sample size for the first group in the fourth stage is                            
       and the cumulated sample size for the second group in the fourth stage is         
The statistic exceeded the cutoff (which equals 4-16) in the last fourth interim analysis (the test 
statistic equals 4.263). So the trial was terminated using all the subjects to conclude that there is 
a significant difference between the two treatments (Table 4-16). 
Table 4-16: Case 4 result for The O’Brien Fleming Neyman Allocation GST procedure. 
Case4 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi-square 
1 4.10 15 15 2 4 30 0.208 
2 4.10 28 32 3 8 60 1.108 
3 4.10 41 49 5 15 90 3.285 
4 4.10 53 67 8 21 120 4.263 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
 
For the fifth case, we divided the sample size into five equal clusters. We used the GST 
procedure with K=5, n=24 and P (K=5, α=.05)=4.16. We failed to reject the Ho in the first three 
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stages, and we recalculated n1 and n2 after each stage. After the first stage, the cumulated sample 
size for the first group in the second stage is                                  
and the cumulated sample size for the second group in the second stage is       . After the 
second stage we recalculate the sample size again. the cumulated sample size for the first group 
in the third stage is                                   and the cumulated 
sample size for the second group in the third stage is          Then after recalculating n1 and 
n2 for the fourth stage, the cumulated sample size for the first group in the third stage is     
                              and the cumulated sample size for the second group 
in the third stage is          The statistic exceeded the cutoff (which equals 4.16) in the four 
interim analysis (the test statistic equals 4.437). So the trial was terminated using 96 subjects to 
conclude that there is a significant difference between the two treatments (Table 4-17). 
Table 4-17: Case 5 result for The O’Brien Fleming Neyman Allocation GST procedure. 
Case5 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 4.16 12 12 3 4 24 0.040 
2 4.16 23 25 6 11 48 0.672 
3 4.16 34 38 8 17 72 2.136 
4 4.16 45 51 10   23 96 4.437 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
As we can see, the third case found there was a difference with just 80 subjects in total, 
which is less than the 120 subjects that would have been used in a conventional clinical trial.  
The following example is to illustrate how the procedure works when there is no difference 
between the two treatments. We simulated the two groups from the same distribution to make 
sure that there is no difference between the means. So we have data for 60 subjects for each 
group that have been simulated from binomial distribution with P=.4 (120 total subjects). We 
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used the O’Brien Fleming GST procedure for different numbers of interim analysis (K=1, 2, 3, 4 
and 5). Again we used: 
 Case 1: n=120, K=1. 
 Case 2: n=60, K=2. 
 Case 3: n=40, K=3. 
 Case 4: n=30, K=4. 
 Case 5: n=24, K=5. 
For all interim analysis in all cases we failed to find a difference (which is expected); all (k/K) 
Chi-square values are less than the alpha values (Table 4-18).  
Table 4-18: The second example results for The O’Brien Fleming Neyman Allocation GST procedure. 
Case1 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total Sample size (k/K)Chi-square 
1 3.84 13/60 17/60 120 0.711 
Case2 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 3.92 15/30 9/30 60 0.881 
2 3.92 26/61 22/59 120 0.356 
Case3 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 4.02 10/20 15/20 40 0.889 
2 4.02 18/41 14/39 80 0.356 
3 4.02 20/61 24/59 120 0.500 
Case4 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 4.10 8/15 4/15 30 0.556 
2 4.10 14/31 11/29 60 0.161 
3 4.10 16/46 19/44 90 0.501 
4 4.10 22/61 25/59 120 0.021 
Case5 analysis results. 
k alpha X1
**
/n1
*
 X2
**
/n2
*
 Total sample size (k/K)Chi -square 
1 4.16 6/12 3/12 24 0.0320 
2 4.16 11/25 8/23 48 0.1702 
3 4.16 12/37 14/35 72 0.2678 
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4 4.16 17/49 19/47 96 0.2690 
5 4.16 23/61 22/59 120 0.0022 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
4.3.4 Testing Type I error 
Recall that the issue with any interim analysis is whether the reuse of data from earlier 
stages affect the Type I error. So for the O’Brien Fleming Neyman Allocation GST procedure we 
are worried about the Type I, because the procedure reuses data which leads to a higher Type I 
error. Again we used a Monte Carlo simulation study to test the Type I error for the O’Brien 
Fleming Neyman Allocation GST procedure (simulating binary data from the same binomial 
distribution with success probabilities (P=.1, .2, .3, .4, .5) with alpha=.01 and .05 to assure the 
null hypothesis is true) for each simulated trial, noting whether we (mistakenly) rejected the null 
hypothesis. We then repeated this process 1,000,000 times and calculated the percentage of 
rejecting the null hypothesis.  
4.3.4.1 Testing Type I error algorithm  
1. The values of the success probability (P), significant alpha (α), total sample size (N), 
number of interim analysis (K) and P (K, α) are chosen. 
2. n=N/K is the total number of subjects for each stage. For the first stage we start with 
the balanced case (N in total).  
3. The sample size needed for the first stage is generated using the same binomial 
distribution (Binomial (P, (N/2K)) Then using the success and failure rates ( ̂ , 
 ̂   ̂ and  ̂ ) to recalculate the new allocation and generate the sample for the 
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following stage, we do the allocation recalculation K-1 times using the cumulative 
success rates.  
4. The O’Brian Fleming test is conducted and checked if we fail to reject the Ho (that 
there is no difference) or there is significant difference and accept the Ha (there is a 
difference between the two groups). 
5. Repeat this 1,000,000 times, then the percentage of accepting the Ha is calculated. 
This will present the Type I error, since we are sure that there is no difference and the 
method indicates that there is a difference (Figure 4-3). 
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Figure 4-3: Testing Type I error algorithm for The O’Brien Fleming Neyman Allocation GST procedure. 
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The results were encouraging: the Type I error rates were mostly less than .05 and .01, and 
in a few cases exceeded .05 and .01 (the maximums were .0518 and .011).  These are even better 
results for the Type I error for the original O’Brien Fleming GST procedure.  
The first simulation was for alpha=.05 starting with a balanced sample size for K equals 1, 
2, 3, 4 and 5. The results are in the following Table (Table 4-19). We can see all the values are 
close to .05. The values for Type I error values are between .0473 and .0518. 
Table 4-19: Type I estimate for alpha=.05 for The O’Brien Fleming Neyman Allocation GST procedure. 
K=5 K=4 
n P Alpha n P Alpha 
72 0.1 0.0473 90 0.1 0.0476 
72 0.2 0.0509 90 0.2 0.0505 
72 0.3 0.0516 90 0.3 0.0513 
72 0.4 0.0514 90 0.4 0.0511 
72 0.5 0.0489 90 0.5 0.0518 
K=3 K=2 
n P Alpha n P Alpha 
120 0.1 0.0482 180 0.1 0.0494 
120 0.2 0.0506 180 0.2 0.0502 
120 0.3 0.0505 180 0.3 0.0500 
120 0.4 0.0508 180 0.4 0.0500 
120 0.5 0.0502 180 0.5 0.0530 
K=1 
n P Alpha 
360 0.1 0.0498 
360 0.2 0.0505 
360 0.3 0.0507 
360 0.4 0.0485 
360 0.5 0.0510 
After that, the second simulations were conducted for alpha=.01 for K equals 1, 2, 3, 4 and 
5. All the values are close to .01. The values for Type I error values are between .009 and .010 
(Table 4-20) Therefore, the O’Brien Fleming Neyman Allocation procedure works well. And we 
can say that the O'Brien Fleming Neyman Allocation procedure has the same Type I error rate as 
that of a fixed one-stage chi-square. 
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Table 4-20: Type I estimate for alpha=.01 for The O’Brien Fleming Neyman Allocation GST procedure. 
K=5 K=4 
n P Alpha n P Alpha 
72 0.1 0.0098 90 0.1 0.0092 
72 0.2 0.0100 90 0.2 0.0099 
72 0.3 0.0101 90 0.3 0.0101 
72 0.4 0.0101 90 0.4 0.0101 
72 0.5 0.0098 90 0.5 0.0099 
K=3 K=2 
n P Alpha n P Alpha 
120 0.1 0.0086 180 0.1 0.0081 
120 0.2 0.0098 180 0.2 0.0098 
120 0.3 0.0100 180 0.3 0.0101 
120 0.4 0.0102 180 0.4 0.0101 
120 0.5 0.0103 180 0.5 0.0105 
K=1 
n b Alpha3 
360 0.1 0.0078 
360 0.2 0.0097 
360 0.3 0.0100 
360 0.4 0.0102 
360 0.5 0.0110 
 
4.3.5 Testing how the O’Brien Fleming Neyman Allocation GST procedure 
affects power 
We used a Monte Carlo simulation to test the power as we did before with original O’Brien 
Fleming GST procedure in Chapter Three. Power presents the case where we reject the null 
hypothesis when there is a “true” difference between treatments. We are interested in testing 
power again, because we want to see if changing the allocation will decrease the power of the 
original O’Brien Fleming procedure. We simulated binary data from different binomial 
distribution with different success probabilities ((P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.4) 
and (P1=.4, P2=.521)  with alpha=.01 and (P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.3), 
(P1=.345, P2=.5) and alpha=.05) to assure the null hypothesis is not true. For each simulated 
trial, we used the O’Brien Fleming Neyman Allocation procedure with the updated critical 
 
 
70 
 
values, noting whether we rejected the null hypothesis. We then repeated this process 1,000,000 
times, and use the percentage of the times we rejected the null hypothesis as an estimated power 
since we are sure that there is a “true” difference. 
4.4.5.1 Testing power algorithm  
1. The values of the success probabilities (P1, P2), significant alpha (α), total sample size 
(N), number of interim analysis (K) and critical value (P (K, α)) are chosen. 
2. Power for N doing the ordinary chi-square test is calculated using nQuery for the use of 
comparison.  
3. n=N/K is the total number of subjects for each stage. For the first stage we start with the 
balanced case (N in total).    
4. The sample size needed for the first stage is generated using the binomial distributions 
(Binomial (P1, (N/2K) and Binomial (P2, (N/2K))) Then using the success rates 
( ̂   ̂   ̂ and  ̂ ) to recalculate the new allocation and generate the sample for the 
following stage, we do the allocation recalculation K-1 times using the cumulative 
success rates.  
5. The O’Brian Fleming Neyman Allocation test is conducted and we check whether we fail 
to reject the Ho (that there is no difference) or accept the Ha which indicates that there is 
a significant difference. 
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6. Repeat steps two to five 1,000,000 times, then the percentage of accepting the Ha is 
calculated (which represents power) since we are sure that there is a difference and the 
method indicates that there is a difference (Figure 4-4). 
 
Figure 4-4: Testing power algorithm for the O’Brian Fleming Neyman Allocation procedure. 
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We chose P1=.3, P2=.4, (α=.05 or .01) and n=(360/K) in balanced case (360 in total) We 
used nQuery to calculate the power needed for the ordinary chi-square for the two cases. For the 
first case, when alpha equals .05 with balanced samples (n1=180 and n2=180) the power is 51%. 
In the result for the O’Brien Fleming Neyman Allocation procedure using the Monte Carlo 
simulation, the power values are from 0.503 to .52 (Table 4-22).The second case when alpha 
equals .01 with balanced samples (n1=180 and n2=180) the power is 27%. The O’Brien Fleming 
Neyman Allocation procedure lead to the power values are from 0.273 to .280 (Table 4-22). 
Table 4-21: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 
          Group 1 proportion, p1 0.300 0.300 
          Group 2 proportion, p2 0.400 0.400 
      n1 180 180 
      n2 180 180 
  N=n1 + n2 360 360 
  Power  51% 27% 
 
Table 4-22: Power estimates using Monte Carlo simulation for different cases. 
 
 
 
 
Moreover, we wanted to test the O’Brien Fleming Neyman Allocation procedure for higher 
power. So we tested for two extra scenarios. First scenario P1=.2, P2=.3, α=.05 and (m1, 
m2)=(300/K, 300/K). We used nQuery to calculate the power needed for the ordinary chi-square 
alpha m1 m2 P1-P2   
Power 
K=1 K=2 K=3 K=4 K=5 iterations 
.01 180 180 0.3-0.4 0.280 0.278 0.277 0.276 0.273 1000000 
.05 180 180 0.3-0.4 0.520 0.510 0.507 0.504 0.503 1000000 
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using. Power equals 80% for the setup of P1=.2, P2=.3, α=.05 and n=300 per group. In the result 
for the O’Brien Fleming Neyman Allocation procedure using the Monte Carlo simulation, the 
power values are from 0.798 to .811 (Table 4-24). Second scenario P1=.2, P2=.4, α=.01 and (m1, 
m2)=(120/K, 120/K). We calculated the power using the nQuery. Power equals 79% for the 
setup of P1=.2, P2=.4, α=.01 and n=120 per group. For the O’Brien Fleming Neyman Allocation 
procedure using the Monte Carlo simulation the power values are from 0.794 to .803 (Table 4-
24).  
Table 4-23: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 
          Group 1 proportion, p1 0.200 0.200 
          Group 2 proportion, p2 0.300 0.400 
      n1 300 120 
      n2 300 120 
  N=n1 + n2 600 240 
  Power  80% 79% 
 
Table 4-24: Power estimates using Monte Carlo simulation for different cases. 
 
 
 
 
 
After using Monte Carlo to calculate the power for the four cases, we had interesting 
results (Table 4-22 and Table 4-24). As we expected when the number of interim analysis 
increases, the power decreases. It is clear that the differences between the powers in each case 
are so small that it can be overlooked. Also most powers are higher than the estimates from 
nQuery. And we have the choice to pick the number of interim analyses that suits any study’s 
needs.      
alpha m1 m2 P1-P2   
Power 
K=1 K=2 K=3 K=4 K=5 iterations 
.05 300 300 0.2-0.3 0.811 0.808 0.803 0.800 0.798 1000000 
.01 120 120 0.2-.04 0.803 0.796 0.788 0.785 0.779 1000000 
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4.4 Extending the O’Brien Fleming Multiple procedure with weighted ns for 
different stages  
4.4.1 Introduction  
The original O’Brien Fleming GST with an equal allocation inquires for equal sample sizes 
for different stages and that will done as follows: we need to choose the total sample size N 
(should be even) and K, then we divide N over K to get each stage sample size n. In this 
extension we are allowing for different sample weights for different stages. In this case we 
choose N (should be even), K and {w1,…, wK} where        and ∑     
 
  . After that we 
calculate ni=round (wi
*
N), if ni is even. Otherwise, ni=round (wi
*
N)+1 , for both cases i=1,…, K-
1 and nK=N-∑   
   
 . 
4.4.2 The O’Brien Fleming Weighted GST procedure 
This GST procedure can be used in any clinical trial which compares two treatments with 
binary outcomes. The data must be collected independently on each treatment. The procedure is 
as follows: the data are reviewed and tested periodically with ni subjects receiving treatment 1 
and treatment 2 for stages i. The allocation will be an equal allocation (ni1=ni2).  
1. First, n11 and n12 subjects are assigned to treatments 1 and 2, respectively (n11and 
n12 must be equal and n1=n11+n12). The experiment is terminated and the 
hypothesis of no difference between treatments rejected if  
     
2
1
l /   P ,  ,K K   where  
2
1
  is the usual Pearson chi-square statistic, α 
is the size of the test, and P (K, α) is a critical value obtained from an O’Brian 
Fleming Table 2.1.  
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2. Otherwise, if the critical value is not exceeded, we collect the next n21 and n22, the 
subjects are randomized and their measurements are observed. 
3. In general, for the kth test the study is terminated and the null hypothesis is 
rejected if      
2   P ,  ,
k
k / K K   where  
2
k
  is the usual Pearson chi-square 
statistic based on all data collected up to the kth test. If not we repeat steps two and 
three. 
4. If after completing K tests
 
2
K
  does not exceed  P ,  K  , the study is terminated 
with the conclusion that the hypothesis of no difference cannot be rejected at α 
level of significance.  
 
 
4.4.3 The O’Brien Fleming Weighted Testing procedure illustrating examples   
      In this section we will provide two examples to demonstrate how the O’Brien Fleming 
Weighted GST procedure works when there is a significant difference or insignificant difference. 
For illustration when there is a significant difference between the groups, we used simulated data 
for 150 subjects for each group (300 total subjects with P1=.3 and P2=.4), then we used the 
O’Brien Fleming procedure with the weighted sample for different number of interim analyses 
(K=1, 2, 3, 4 and 5), and specified which case required the fewest subjects. 
 Case 1: n=300, K=1. 
 Case 2: w1=60%, w2=40%, then n1=180 and n2=120 for K=2. 
 Case 3: w1=45%, w2=30%, w3=25%, then n1=136, n2=90 and n3=74 for K=3. 
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 Case 4: w1=40%, w2=30%, w3=20%, w4=10%, then n1=120, n2=90, n3=60 and n4=30 
for K=4. 
 Case 5: w1=30%, w2=25%, w3=20%, w4=15%, w5=10%, then n1=90, n2=76, n3=60, 
n4=46 and n5=28 for K=5. 
 
For the first case K=1 and n1=n2=150, so we used P (K=1, α=.05)=3.84. We used all of the 
sample size at once. Then we used the O’Brien Fleming Weighted GST procedure (that is the 
same as chi-square when K=1). The O’Brien Fleming test statistic equals 1.177 which is less 
than 3.84. So the statistic for this interim analysis was not significant, indicating we failed to find 
a difference between the treatments (Table 4-25). 
 
Table 4-25: Case 1 result for the O’Brien Fleming Weighted Testing procedure. 
Case1 analysis results. 
k alpha  n1
* 
n2
* 
X1
**
 X2
**
 Total Sample size (k/K)Chi-square 
1 3.84 150 150 47 58 300    1.177 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
 
For the second case, we divided the sample size into two clusters, so K=2, n=180 for the 
first stage, n=120 for the second stage and we used P (K=2, α=.05)=3.92. Then we used the 
O’Brien Fleming Weighted GST procedure, but we could not terminate the trial in the first 
interim analysis, because the statistic did not exceed the P (K=2, α=.05) (statistic equals .436 
which is less than 3.92). Therefore we had to use the entire sample size of 150 for each group.  
The statistic for the second interim analysis was significant. The test statistic is equal 5.202 that 
is greater than 3.92, indicating a significant difference between the treatments (Table 4-26). 
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Table 4-26: Case 2 result for the O’Brien Fleming Weighted Testing procedure. 
Case2 analysis results. 
k alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 3.92 90 90 29 35 180 0.436 
2 3.92 150 150 45 64 300 5.202 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
In the third case, we divided the sample size into three clusters, and then we used the O’Brien 
Fleming Weighted GST procedure with K=3, n=136 for the first stage, n=90 for the second 
stage, n=74 for the third stage and P (K=3, α=.05)=4.02. We failed to reject the Ho in the first 
stage. The statistic exceeded the cutoff (which equals 4.02) in the second interim analysis (the 
test statistic equals 6.904). So the trial was terminated just using 226 subjects to conclude that 
there is a significant difference between the two treatments (Table 4-27). 
Table 4-27: Case 3 result for the O’Brien Fleming Weighted Testing procedure. 
Case3 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 4.02 68 68 17 31 136 2.103 
2 4.02 113 113 27 50 226 6.904 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
In the fourth case, we divided the sample size into four clusters, and then we used the O’Brien 
Fleming Weighted GST procedure with K=4, n=120 for the first stage, n=90 for the second 
stage, n=60 for the third stage, n=30 for the fourth stage and P (K=4, α=.05)=4.16. We failed to 
reject the Ho in the first stage. Then the statistic exceeded the cutoff (which equals 4.16) in the 
second interim analysis (the test statistic equals 4.692). So the trial was terminated using 210 
subjects to conclude that there is a significant difference between the two treatments (Table 4-
28). 
Table 4-28: Case 4 result for the O’Brien Fleming Weighted Testing procedure. 
Case4 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi-square 
1 4.10 60 60 15 27 120 1.319 
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2 4.10 105 105 25 46 210 4.692 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
For the fifth case, we divided the sample size into five clusters. We used the O’Brien 
Fleming Weighted GST procedure with K=4, n=90 for the first stage, n=76 for the second stage, 
n=60 for the third stage, n=46 for the fourth stage, n=28 for the last stage and P (K=5, 
α=.05)=4.16. We failed to reject the Ho in the first two stages. The statistic exceeded the cutoff 
(which equals 4.16) in the fourth interim analysis (the test statistic equals 6.285). So the trial was 
terminated using 226 subjects to conclude that there is a significant difference between the two 
treatments (Table 4-29). 
Table 4-29: Case 5 result for the O’Brien Fleming Weighted Testing procedure. 
Case5 analysis results. 
K alpha n1
*
 n2
*
 X1
**
 X2
**
 Total sample size (k/K)Chi -square 
1 4.16 45 45 11 21 90 0.970 
2 4.16 83 83 19 37 166 3.492 
3 4.16 113 113 28  50 226 5.685 
*these are the cumulated sample sizes. **X1  and X2 are success counts. 
As we can see, the fourth case found there was a difference with just 210 subjects in total, 
which is less than the 300 subjects that would have been used in a conventional clinical trial. 
The following example is to illustrate how the procedure works when there is no difference 
between the two treatments. We simulated the two groups from the same distribution to make 
sure that there is no difference between the means. So we have data for 150 subjects for each 
group that have been simulated from binomial distribution with P=.3 (300 total subjects). We 
used the O’Brien Fleming GST procedure for different numbers of interim analysis (K=1, 2, 3, 4 
and 5). Again we used: 
 Case 1: n=300, K=1. 
 Case 2: w1=60%, w2=40%, then n1=180 and n2=120 for K=2. 
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 Case 3: w1=45%, w2=30%, w3=25%, then n1=136, n2=90 and n3=74 for K=3. 
 Case 4: w1=40%, w2=30%, w3=20%, w4=10%, then n1=120, n2=90, n3=60 and n4=30 
for K=4. 
 Case 5: w1=30%, w2=25%, w3=20%, w4=15%, w5=10%, then n1=90, n2=76, n3=60, 
n4=46 and n5=28 for K=5. 
For all interim analyses in all cases we failed to find a difference (which is expected); all 
(k/K) Chi-square values are less than the alpha values (Table 4-30).  
Table 4-30: The second example results for the O’Brien Fleming Weighted Testing procedure. 
Case1 analysis results. 
k alpha X1
**
/n1 X2
**
/n2 Total Sample size (k/K)Chi-square 
1 3.84 47/150 43/150 300 0.254 
Case2 analysis results. 
k alpha X1
**
/n1 X2
**
/n2 Total sample size (k/K)Chi-square 
1 3.92 29/90 26/90 180 0.117 
2 3.92 45/150 48/150 300 0.140 
Case3 analysis results. 
k alpha X1
**
/n1 X2
**
/n2 Total sample size (k/K)Chi-square 
1 4.02 17/68 24/68 136 0.570 
2 4.02 27/113 38/113 226 1.742 
3 4.02 38/150 50/150 300 2.315 
Case4 analysis results. 
k alpha X1
**
/n1 X2
**
/n2 Total sample size (k/K)Chi-square 
1 4.10 15/60 21/60 120 0.375 
2 4.10 25/105 35/105 210 1.116 
3 4.10 34/135 45/135 270 1.624 
4 4.10 40/150 48/150 300 1.029 
Case5 analysis results. 
k alpha X1
**
/n1 X2
**
/n2 Total sample size (k/K)Chi-square 
1 4.16 11/45 16/45 90 0.265 
2 4.16 19/83 28/83 166 0.962 
3 4.16 28/113 38/113 226 1.284 
4 4.16 37/136 44/136 272 0.689 
5 4.16 40/150 48/150 300 1.029 
4.4.4 Testing Type I error 
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Recall that the issue with any interim analysis is whether the reuse of data from earlier stages affect 
the Type I error, so we are worried having this issue for the O’Brien Fleming Weighted GST procedure. 
Again we used a Monte Carlo simulation study to test the Type I error for the O’Brien Fleming Weighted 
GST procedure (simulating binary data from the same binomial distribution with success probabilities 
(P=.1, .2, .3, .4, .5) with alpha=.01 and .05 to assure the null hypothesis is true) for each simulated trial, 
noting whether we (mistakenly) rejected the null hypothesis. We then repeated this process 1,000,000 
times and calculated the percentage of rejecting the null hypothesis. We will test the Type 1 error for 
three situations when the weights are decreasing, increasing and non-monotonic. 
Testing Type I error algorithm  
1. The values of the success probability (P), significant alpha (α), total sample size (N), 
number of interim analysis (K) and critical value (P (K, α)) are chosen. 
2. Calculate the sample size ni for each stage i using the weight wi for that stage.  
3. The sample size needed for each stage is generated using the same binomial 
distribution (Binomial (P, (ni/2))).  
4. The O’Brian Fleming Weighted Multiple test is conducted and checked if we fail to 
reject the Ho (that there is no difference) or there is significant difference and accept 
the Ha (there is a difference between the two groups). 
5. Repeat this 1,000,000 times, then the percentage of accepting the Ha is calculated. 
This will present the Type I error, since we are sure that there is no difference and the 
method indicates that there is a difference (Figure 4.5). 
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Figure 4-5: Testing Type I error algorithm for the O’Brian Fleming Weighted Multiple procedure. 
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The results were supporting the procedure: the Type I error rates were around .05 and .01. 
We studied many scenarios divided into three categories when the weights are decreasing, 
increasing and in non-monotonic order. In all cases the Type I error was close to .05 and .01. 
Better results were for the decreasing weights and the non-monotonic weights, and the worse 
were for increasing weights but they are still acceptable . We included some examples to show 
the Type I error rates. The first three simulations were for alpha=.05 and the following three 
simulation for alpha=.01 with different sizes for K equals 1(with n1=180), 2 (with n1=100, n2=80 
for the decreasing case and n1=80, n2=100 for the increasing case), 3(with n1=80, n2=60, n3=40 
for the decreasing case, n1=80 n2=60, n3=40 for the increasing case and n1=80, n2=40, n3=60 for 
the non-monotonic case), 4(with n1=70, n2=56, n3=34, n4=20  for the decreasing case, n1=20 
n2=34, n3=46 , n4=70  for the increasing case and n1=90, n2=10, n3=52, n4=28 for the non-
monotonic case) and 5 (with n1=60, n2=50, n3=40, n4=20, n5=10  for the decreasing case, n1=10 
n2=20, n3=40 , n4=50, n5=60 for the increasing case and n1=50, n2=20, n3=40, n4=10, n5=60  for 
the non-monotonic case). The results are in the following Table s (Table 4-31-Table 4-36). We 
can see the values for Type I error for alpha=.05 with decreasing weights, values are between 
.0420 and .0518.Also, Type I error for alpha=.05 with increasing weights, values are between 
.0484 and .0566. Then, for the non-monotonic case with alpha=.05, the Type I error values 
ranges from .0438 to.0524. After that, for alpha=.01 case, the values for Type I error with 
decreasing weights are between .0083 and .0101. Also, Type I error for increasing weights, 
values are between .0088 and .0118. Then, for the non-monotonic case, the Type I error values 
are from .0086 to .0115.Thus, the O’Brien Fleming Weighted GST procedure works well. And 
the procedure has the same Type I error rate as that of a fixed one-stage chi-square. 
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Table 4-31: Type I estimate for alpha=.05 with decreasing weights.  
K=5 K=4 
n1,n2,n3,n4, n5 P Alpha n1,n2,n3,n4 P Alpha 
60,50,40,20,10 0.1 0.0434 70,56,34,20 0.1 0.0476 
60,50,40,20,10 0.2 0.0433 70,56,34,20 0.2 0.0505 
60,50,40,20,10 0.3 0.0436 70,56,34,20 0.3 0.0513 
60,50,40,20,10 0.4 0.0440 70,56,34,20 0.4 0.0511 
60,50,40,20,10 0.5 0.0420 70,56,34,20 0.5 0.0518 
K=3 K=2 
n1,n2,n3 P Alpha n1,n2 P Alpha 
80,60,40 0.1 0.0494 100,80 0.1 0.0448 
80,60,40 0.2 0.0488 100,80 0.2 0.0459 
80,60,40 0.3 0.0482 100,80 0.3 0.0458 
80,60,40 0.4 0.0492 100,80 0.4 0.0474 
80,60,40 0.5 0.0471 100,80 0.5 0.0432 
K=1 
n1 P Alpha 
180 0.1 0.0498 
180 0.2 0.0505 
180 0.3 0.0507 
180 0.4 0.0485 
180 0.5 0.0510 
 
Table 4-32: Type I estimate for alpha=.05 with increasing weights. 
K=5 K=4 
n1,n2,n3,n4, n5 P Alpha n1,n2,n3,n4 P Alpha 
10,20,40,50,60 0.1 0.0535 20,34,56,70 0.1 0.0531 
10,20,40,50,60 0.2 0.0554 20,34,56,70 0.2 0.0547 
10,20,40,50,60 0.3 0.0558 20,34,56,70 0.3 0.0539 
10,20,40,50,60 0.4 0.0557 20,34,56,70 0.4 0.0566 
10,20,40,50,60 0.5 0.0549 20,34,56,70 0.5 0.0508 
K=3 K=2 
n1,n2,n3 P Alpha n1,n2 P Alpha 
40,60,80 0.1 0.0526 80,100 0.1 0.0484 
40,60,80 0.2 0.0525 80,100 0.2 0.0504 
40,60,80 0.3 0.0520 80,100 0.3 0.0501 
40,60,80 0.4 0.0532 80,100 0.4 0.0493 
40,60,80 0.5 0.0503 80,100 0.5 0.0534 
K=1 
n1 P Alpha 
360 0.1 0.0498 
360 0.2 0.0505 
360 0.3 0.0507 
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360 0.4 0.0485 
360 0.5 0.0510 
 
Table 4-33: Type I estimate for alpha=.05 with non-monotonic weights.  
K=5 K=4 
n1,n2,n3,n4, n5 P Alpha n1,n2,n3,n4 P Alpha 
50,20,40,10,60 0.1 0.0512 90,10,52,28 0.1 0.0438 
50,20,40,10,60 0.2 0.0520 90,10,52,28 0.2 0.0440 
50,20,40,10,60 0.3 0.0522 90,10,52,28 0.3 0.0477 
50,20,40,10,60 0.4 0.0524 90,10,52,28 0.4 0.0493 
50,20,40,10,60 0.5 0.0512 90,10,52,28 0.5 0.0442 
K=3 
n1,n2,n3 P Alpha 
80,40,60 0.1 0.0494 
80,40,60 0.2 0.0488 
80,40,60 0.3 0.0482 
80,40,60 0.4 0.0492 
80,40,60 0.5 0.0471 
 
 
Table 4-34: Type I estimate for alpha=.01 with decreasing weights 
K=5 K=4 
n1,n2,n3,n4, n5 P Alpha n1,n2,n3,n4 P Alpha 
60,50,40,20,10 0.1 0.0084 70,56,34,20 0.1 0.0085 
60,50,40,20,10 0.2 0.0088 70,56,34,20 0.2 0.0085 
60,50,40,20,10 0.3 0.0088 70,56,34,20 0.3 0.0092 
60,50,40,20,10 0.4 0.0088 70,56,34,20 0.4 0.0092 
60,50,40,20,10 0.5 0.0098 70,56,34,20 0.5 0.0100 
K=3 K=2 
n1,n2,n3 P Alpha n1,n2 P Alpha 
80,60,40 0.1 0.0083 100,80 0.1 0.0098 
80,60,40 0.2 0.0087 100,80 0.2 0.0100 
80,60,40 0.3 0.0087 100,80 0.3 0.0100 
80,60,40 0.4 0.0085 100,80 0.4 0.0099 
80,60,40 0.5 0.0085 100,80 0.5 0.0101 
K=1 
n1 P Alpha 
180 0.1 0.0098 
180 0.2 0.0100 
180 0.3 0.0101 
180 0.4 0.0100 
180 0.5 0.0098 
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Table 4-35: Type I estimate for alpha=.01 with increasing weights  
K=5 K=4 
n1,n2,n3,n4, n5 P Alpha n1,n2,n3,n4 P Alpha 
10,20,40,50,60 0.1 0.0099 20,34,56,70 0.1 0.0088 
10,20,40,50,60 0.2 0.0105 20,34,56,70 0.2 0.0102 
10,20,40,50,60 0.3 0.0107 20,34,56,70 0.3 0.0103 
10,20,40,50,60 0.4 0.0107 20,34,56,70 0.4 0.0105 
10,20,40,50,60 0.5 0.0118 20,34,56,70 0.5 0.0093 
K=3 K=2 
n1,n2,n3 P Alpha n1,n2 P Alpha 
40,60,80 0.1 0.0096 80,100 0.1 0.0097 
40,60,80 0.2 0.0098 80,100 0.2 0.0099 
40,60,80 0.3 0.0101 80,100 0.3 0.0100 
40,60,80 0.4 0.0095 80,100 0.4 0.0100 
40,60,80 0.5 0.0098 80,100 0.5 0.0098 
K=1 
n1 P Alpha 
180 0.1 0.0098 
180 0.2 0.0100 
180 0.3 0.0101 
180 0.4 0.0100 
180 0.5 0.0098 
 
 
Table 4-36: Type I estimate for alpha=.01 with non-monotonic weights 
K=5 K=4 
n1,n2,n3,n4, n5 P Alpha n1,n2,n3,n4 P Alpha 
50,20,40,10,60 0.1 0.0098 90,10,52,28 0.1 0.0086 
50,20,40,10,60 0.2 0.0103 90,10,52,28 0.2 0.0094 
50,20,40,10,60 0.3 0.0104 90,10,52,28 0.3 0.0095 
50,20,40,10,60 0.4 0.0103 90,10,52,28 0.4 0.0094 
50,20,40,10,60 0.5 0.0115 90,10,52,28 0.5 0.0100 
K=3 
n1,n2,n3 P Alpha 
80,40,60 0.1 0.0095 
80,40,60 0.2 0.0099 
80,40,60 0.3 0.0100 
80,40,60 0.4 0.0096 
80,40,60 0.5 0.0102 
 
4.4.5 Testing how O’Brien Fleming Weighted GST procedure affects power 
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We have used a Monte Carlo simulation to test the power previously. Power presents the 
case where we reject the null hypothesis when there is a “true” difference between treatments. 
We are interested in testing power again, because we want to see if having different sample sizes 
for different stages will decrease the power of the original O’Brien Fleming procedure. We 
simulated binary data from different binomial distributions with different success probabilities 
((P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.4) and (P1=.4, P2=.521)  with alpha=.01 and 
(P1=.3, P2=.4), (P1=.3, P2=.5), (P1=.2, P2=.3), (P1=.345, P2=.5) and alpha=.05) to assure the 
null hypothesis is not true. We are doing that for different values of K, 1(with w1=100%), 2 (with 
w1=60%, w2=40% for the decreasing case and w1=40%, w2=60% for the increasing case), 3(with 
w1=50%, w2=30%, w3=20% for the decreasing case, w1=20% w2=30%, w3=50% for the 
increasing case and w1=50%, w2=20%, w3=30% for the non-monotonic case), 4(with w1=40%, 
w2=30%, w3=20%, w4=10%  for the decreasing case, w1=10%   w2=20%, w3=30% , w4=40%  for 
the increasing case and w1=30%, w2=10%, w3=20%, w4=40% for the non-monotonic case) and 5 
(with w1=35%, w2=20%, w3=20%, w4=15%, w5=10%  for the decreasing case, w1=10% 
w2=15%, w3=20% , w4=20%, w5=35% for the increasing case and w1=10%, w2=20%, w3=35%, 
w4=15%, w5=20%  for the non-monotonic case).  For each simulated trial, we used the O’Brien 
Fleming Weighted procedure with the updated critical values, noting whether we rejected the 
null hypothesis. We then repeated this process 1,000,000 times, and use the percentage of the 
times we rejected the null hypothesis as an estimated power since we are sure that there is a 
“true” difference. 
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Testing power algorithm  
1. The values of the success probabilities (P1, P2), significant alpha (α), total sample size 
(N), number of interim analysis (K) and critical value (P (K, α)) are chosen. 
2. Power for N doing the ordinary chi-square test is calculated using nQuery for the use 
of comparison.  
3. Calculate the sample size ni  for each stage i using the weight wi for that stage.  
4. The sample size needed for each stage is generated using the binomial distributions 
(Binomial (P1, (ni/2)) and Binomial (P2, (ni/2)).  
5. The O’Brian Fleming Weighted GST procedure is conducted and we check whether 
we fail to reject the Ho (that there is no difference) or accept the Ha which indicates 
that there is a significant difference. 
6. Repeat steps two to five 1,000,000 times, then the percentage of accepting the Ha is 
calculated (which represents power) since we are sure that there is a difference and 
the method indicates that there is a difference (Figure 4-6). 
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Figure 4-6: Testing power algorithm the O’Brian Fleming Weighted Multiple procedure. 
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We chose P1=.3, P2=.4, (α=.05 or .01) and N=360 We used nQuery to calculate the power 
needed for the ordinary chi-square for the two cases. For the first case, when alpha equals .05 
with balanced samples (n1=180 and n2=180) the power is 51%. In the result for the O’Brien 
Fleming Weighted GST procedure using the Monte Carlo simulation, the power values are from 
0.492 to .517 (Table 4-38-Table 4-40).The second case when alpha equals .01 with balanced 
samples (n1=180 and n2=180) the power is 27%. The O’Brien Fleming Weighted GST procedure 
power values are from 0.265 to .279 (Table 4-38-Table 4-40). 
 
Table 4-37: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 
          Group 1 proportion, p1 0.300 0.300 
          Group 2 proportion, p2 0.400 0.400 
      n1 180 180 
      n2 180 180 
  N=n1 + n2 360 360 
  Power  51% 27% 
 
Table 4-38: Power estimates using Monte Carlo simulation for different cases with decreasing weights. 
 
 
 
 
Table 4-39 : Power estimates using Monte Carlo simulation for different cases for increasing weights. 
 
 
 
 
 
alpha m1 m2 P1-P2   
Power 
K=1 K=2 K=3 K=4 K=5 iterations 
.01 180 180 0.3-0.4 0.279 0.265 0.275 0.273 0.270 1000000 
.05 180 180 0.3-0.4 0.517 0.501 0.498 0.492 0.499 1000000 
alpha m1 m2 P1-P2   
Power 
K=1 K=2 K=3 K=4 K=5 iterations 
.01 180 180 0.3-0.4 0.279 0.278 0.277 0.277 0.276 1000000 
.05 180 180 0.3-0.4 0.517 0.511 0.504  0.504 .505 1000000 
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Table 4-40: Power estimates using Monte Carlo simulation for different cases for non-monotonic weights. 
 
 
 
 
Moreover, we wanted to test the O’Brien Fleming Weighted GST procedure for higher 
power. So we tested for two extra scenarios. First scenario P1=.2, P2=.3, α=.05 and N=600. We 
used nQuery to calculate the power needed for the ordinary chi-square, power equals 80% for the 
setup of P1=.2, P2=.3, α=.05 and n=300 per group. In the result for the O’Brien Fleming 
Weighted GST procedure using the Monte Carlo simulation, the power values are from 0.798 to 
.811 (Table 4-42-Table 4-45). Second scenario P1=.2, P2=.4, α=.01 and N=240. We calculated 
the power using nQuery. Power equals 79% for the setup of P1=.2, P2=.4, α=.01 and n=120 per 
group. The power values are from 0.794 to .803 (Table 4-42-Table 4-45) for the O’Brien 
Fleming Weighted GST procedure using the Monte Carlo simulation.  
Table 4-41: the nQuery results for calculating the power. 
  Test significance level alpha 0.050 0.010 0.050 0.010 
          Group 1 proportion, p1 0.200 0.200 0.345 0.400 
          Group 2 proportion, p2 0.300 0.400 0.500 0.521 
      n1 300 120 120 300 
      n2 300 120 240 600 
  N=n1 + n2 600 240 360 900 
  Power  80% 79% 84% 80% 
 
 
Table 4-42: Power estimates using Monte Carlo simulation for different cases with decreasing weights. 
alpha m1 m2 P1-P2   
Power 
K=3 K=4 K=5 iterations 
.01 180 180 0.3-0.4 0.276 0.278 0.273 1000000 
.05 180 180 0.3-0.4 0.501 0.504 .500 1000000 
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Table 4-43: Power estimates using Monte Carlo simulation for different cases with increasing weights. 
 
 
 
 
 
Table 4-44: Power estimates using Monte Carlo simulation for different cases for non-monotonic weights. 
 
 
 
 
 
After using Monte Carlo to calculate the power for the four cases, we had interesting 
results (Table 4-42 and Table 4-44). As we expected when the number of interim analysis 
increases, the power decreases. It is clear that the differences between the powers in each case 
are so small that it can be overlooked. Also most powers are higher than the estimates from 
nQuery. And we have the choice to pick the number of interim analyses that suits any study’s 
needs. 
alpha m1 m2 P1-P2 
Power 
K=1 K=2 K=3 K=4 K=5 iterations 
.05 300 300 0.2-0.3 0.811 0.807 0.802 0.796 0.795 1000000 
.01 120 120 0.2-.04 0.802 0.797 0.796 0.793 0.808 1000000 
alpha m1 m2 P1-P2   
Power 
K=1 K=2 K=3 K=4 K=5 iterations 
.05 300 300 0.2-0.3 0.811 0.808 0.804 0.802 0.801 1000000 
.01 120 120 0.2-.04 0.802 0.797 0.796 0.795 0.795 1000000 
alpha m1 m2 P1-P2   
Power 
  K=3 K=4 K=5 iterations 
.05 300 300 0.2-0.3   0.803 0.802 0.799 1000000 
.01 120 120 0.2-.04   0.797 0.796 0.793 1000000 
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4.5 Conclusion 
In this chapter we extended the O’Brien Fleming GST procedure for the balanced case in 
three ways: using the Optimal Allocation, Neyman Allocation and weighted sample size for 
different stages. We explained every one of these new methods with the extensions and we tested 
the two concepts we care about in any statistical test power and Type 1 error. We showed that 
the three extensions for the O’Brien Fleming GST procedure worked well with respect to the 
power and Type I error. We feel comfortable that any of these three extension can be applied 
with the O’Brien Fleming GST procedure without further adjustment. Comparing the Type I 
error for the three new procedures to the original O’Brien Fleming GST procedure, we can see 
that the three procedures have less estimated Type I error than the original procedure. The 
original O’Brien Fleming GST procedure has an estimate for Type I error that is less than .0534 
(for α=.05) and less than .0112 (for α=.01). On the other hand, for the procedure with Optimal 
allocation the estimate for Type I error is less than .0519 (for α=.05) and less than .0103 (for 
α=.01), for the procedure with Nyman allocation the estimate for Type I error is less than .0518 
(for α=.05) and less than .011 (for α=.01) and for the procedure with decreasing sample weights 
the estimate for Type I error is less than .0518 (for α=.05) and less than .010 (for α=.01). For the 
procedure with non-monotonic sample weights the estimate for Type I error was so close to the 
original procedure, the Type I error is less than .052 (for α=.05) and less than .0115 (for α=.01). 
The only procedure with higher Type I error is for the procedure with increasing sample weights, 
when the estimate for Type I error is less than .0566 (for α=.05) and less than .018 (for α=.01). 
Now, the original O’Brien Fleming GST procedure has estimates for powers for the four cases 
which are higher than .5, .273, 0.799, and 0.794. For the same cases, the other procedures’ power 
estimates were so close. The procedure with the Optimal allocations estimated the powers as 
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follows (.499, .269, 0.797, and 0.779), the procedure with the Neyman allocations estimated the 
powers as follows (.503, .273, 0.798, and 0.794), and the procedure with different sample 
weights estimated the powers as follows (.492, .265, 0.798, and 0.794).  
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Chapter 5 : Discussion, Limitations and Future Work 
5.1 Discussion  
In this dissertation we provided three extensions of a well-known sequential group testing 
procedure presented by O’Brien and Fleming30. First, we corrected the stopping bounds for 
O’Brian Fleming GST procedure using the same method they used to estimate the stopping 
bounds with a larger number of iterations.  Then we showed that the O’Brien Fleming procedure 
has the same Type I error rate and desired power as that of a fixed one-stage chi-square test. We 
also extended the O’Brien Fleming GST procedure in the balanced case in three ways. The first 
extension is combining the O’Brien Fleming GST procedure with optimal allocation. The second 
extension is combining the O’Brien Fleming GST procedure with the Neyman allocation. The 
last extension involves changing the total sample size from stage to stage in the procedure. We 
showed that the three extensions for the O’Brien Fleming GST procedure worked well with 
respect to the power and Type I error. We feel comfortable that any of these three extensions can 
be applied with the O’Brien Fleming GST procedure without further adjustment. 
The trade-off between power and expected treatment failures is the tool to decide between 
choosing the Optimal extension or the Neyman extension. The optimal allocation extension will 
result in fewer treatment failures without sacrificing power. The Neyman allocation  will result 
higher power yet with an increased chance of increasing the number of treatment failures. When 
the difference between the success probabilities of the treatments are not expected to be small 
and the rates are below 0.5, Neyman allocation will not sacrifice number of successes.  Though 
selecting unbalanced block assignments will create unequally sized groups, there may be 
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biological reasons for creating such groups (e.g. small blocks at the beginning of toxicity trials; 
large blocks at the beginning of efficacy trials). In such cases, the blocking assignment can be 
designed with those biological considerations in mind with little consequence to the statistical 
integrity of the trial.  
5.2 limitations 
Some limitations or practical problems may appear when using the O'Brien Fleming GST 
procedure or using the procedure with any of the three extensions. First, the method allows for 
stopping the trial with the conclusion that the experimental treatment is effective. It doesn’t go 
the other way, meaning that this procedure will not stop the trial earlier if the experimental 
treatment is not effective (unless futility or toxicity is the measured endpoint), which could be a 
waste of time and resources. Second, any of these extensions of the O’Brien Fleming procedure 
are not be appropriate for clinical trials with delayed responses, as the delayed response will 
prohibit changes to the allocation weights. Not however, that the approach can still be used, the 
adaptation will simply slow down. Third, the procedure depends on an approximation method to 
find the stopping bounds, and when comparing the stopping bounds values when K=1 to the 
stopping bounds for the usual chi-square with degree of freedom 1, we can see a small negative 
bias. Fixing this bias needs more investigation and possibly a different approximation method 
than that used by O’Brien and Fleming. Nevertheless, the results from the Monte Carlo 
simulations shows that the procedure has the desired Type I error and power. 
5.3 Future work 
 
Lui K. (1994)proposed a generalization of the O’Brien Fleming GST procedure which 
generalizes their GST method to more than two groups. We plan ti study this procedure to see if 
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our proposed extensions work for that method as well. We will be working on the Optimal and 
Neyman allocation rules and check if they work when we start from unbalanced allocation for 
the sample size in the first stage. If yes, we will test extending the O’Brien Fleming GST when 
we have  unbalanced sample sizes. The O’Brien Fleming GST procedure uses k/K as a weight 
for their test statistic, we will try to find another weights that works with the stopping bounds. 
We are going to study the monotonic property for the stopping bounds for any Group Sequential 
testing procedure, and try to prove that when we increase the interim analysis numbers we need 
to increase the stopping bound we use.  
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Appendix  
Table A.1: Data from a two‐arm clinical trial for the first example in the 2nd chapter.  
Accrual treat1 treat2 Accrual treat1 treat2 Accrual treat1 treat2 
1 0 0 21 1 0 41 0 0 
2 0 0 22 0 1 42 0 1 
3 1 0 23 0 0 43 0 0 
4 0 0 24 1 1 44 0 1 
5 0 0 25 1 1 45 0 0 
6 1 0 26 0 0 46 0 1 
7 0 1 27 1 1 47 0 0 
8 0 1 28 1 1 48 0 0 
9 0 1 29 0 1 49 0 0 
10 0 1 30 1 1 50 0 0 
11 0 0 31 0 0 51 0 1 
12 1 1 32 0 1 52 0 0 
13 0 1 33 0 1 53 1 1 
14 0 1 34 1 1 54 0 0 
15 0 0 35 0 1 55 0 0 
16 0 1 36 0 0 56 0 0 
17 0 0 37 1 0 57 0 1 
18 1 1 38 0 0 58 0 1 
19 0 1 39 0 1 59 0 0 
20 0 1 40 1 1 60 1 0 
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Table A.2: Simulated for the second example in the 2nd chapter.  
Accrual treat1 treat2 Accrual treat1 treat2 Accrual treat1 treat2 
1 0 1 21 1 1 41 0 0 
2 0 1 22 1 0 42 0 1 
3 0 0 23 1 1 43 0 0 
4 1 0 24 0 0 44 0 1 
5 1 1 25 1 0 45 1 0 
6 0 1 26 1 0 46 1 0 
7 1 1 27 1 0 47 1 0 
8 0 0 28 0 1 48 1 0 
9 1 0 29 0 1 49 0 1 
10 1 0 30 0 0 50 0 1 
11 0 0 31 0 0 51 0 0 
12 0 1 32 0 0 52 0 0 
13 1 1 33 0 0 53 1 0 
14 1 1 34 0 0 54 1 1 
15 0 0 35 0 0 55 0 0 
16 0 0 36 0 0 56 1 1 
17 1 1 37 0 0 57 0 0 
18 1 0 38 1 1 58 0 0 
19 1 0 39 0 0 59 0 1 
20 0 1 40 0 1 60 1 1 
 
a.1 O’Brian Fleming table using O’Brian Fleming method*/ 
Data simulation; 
   Do k=1 to 10000000; /
*
calculate the Max{Tn} for 10,000,000 sample
*
/ 
       Do j=1 to 5;     /
*
 the do loop here is to calculate the max{Tn} for the five cases of K 
in the paper 
*
/ 
          s=0; 
          n=0; 
          Do i=1 to j;  /
*
this loop is to calculate the Tn for 1 to j then take the Max
*
/ 
          t=rannor(i+j+k); 
          u1=t+s; 
          s1=u1
**
2/j; 
          u=max(n,s1); 
          s=u1; 
          n=u; 
 
 
99 
 
        end; 
     output;/
*
 output just the max
*
/ 
     end; 
   end; 
run; 
 
Proc sort data= simulation; /
*
sort the data by j
*
/ 
By j; 
Run; 
 
Proc Univariate data= simulation noprint; by j; 
var u;             /
*
find the percintiles for the  max{Tn}
*
/ 
output out=table pctlpre=P_ pctlpts= 50, 90 to 99 by 1,99.5,99.9; 
run; 
 
proc transpose data=table out=finaltable; 
run;  
proc print data=finaltable; 
run; 
 
Table A.3: Standard deviation for the corrected stopping bounds based on ten simulations groups. 
 Number of stages (K) 
Alpha 1 2 3 4 5 
0.5 0.000313 0.000290 0.000369 0.000324 0.000441 
0.1 0.001822 0.001714 0.001697 0.001127 0.001080 
0.09 0.002279 0.001695 0.001788 0.001173 0.001291 
0.08 0.002204 0.001823 0.001623 0.000843 0.001658 
0.07 0.002488 0.002087 0.001878 0.000963 0.001673 
0.06 0.002687 0.002020 0.002179 0.001307 0.001795 
0.05 0.002741 0.002487 0.002486 0.001857 0.001982 
0.04 0.003660 0.002028 0.002959 0.001892 0.002214 
0.03 0.003399 0.002963 0.002965 0.003297 0.002651 
0.02 0.003427 0.004381 0.003431 0.002722 0.003302 
0.01 0.005338 0.006362 0.004375 0.004015 0.004689 
0.005 0.008497 0.011059 0.004978 0.009358 0.005427 
0.001 0.008942 0.018704 0.012504 0.016217 0.018554 
 
a.2 Sample for SAS coding to calculate Type I error or Power 
%let iterations=1000000; 
 
%macro alpha; 
 
%do stages_no=1 %to 5; 
%let a=180/&stages_no ; 
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  %do bb=3 %to 3; 
   
 
  %let b=&bb/10; 
data test1; 
do j=1 to &iterations; 
y=0; 
do k=1 to 5; 
group=1; 
outcome=1; 
h=1
*
j+13
*
k; 
y=y+ranbin(h,&a,&b); 
output; 
   outcome=0; 
   y=(k
*
&a)-y; 
   output; 
y=(k
*
&a)-y; 
 end; 
 
end; 
 
run; 
data test2; 
%let b2=&b; 
%let a2=2
*
&a; 
do j=1 to &iterations; 
y=0; 
do k=1 to 5; 
group=2; 
outcome=1; 
h=1000
*
j+10
*
k; 
c=&b+.1; 
y=y+ranbin(h,&a2,&b2); 
output; 
   outcome=0; 
   y=(k
*
&a2)-y; 
   output; 
y=(k
*
&a2)-y; 
 end; 
end; 
 
run; 
data test; 
set test1 test2; 
run; 
proc sort; 
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by j k outcome;  
run; 
data test_1; 
set test; 
by j k outcome; 
if first.outcome then y1=y; else y1+y; 
run; 
data test; 
set test_1; 
by j k outcome; 
if last.outcome and y1=0 then y=y+.05; 
run; 
 
 
proc sort data=test; 
by j  k  group; 
run;  
proc freq data=test noprint; 
   tables group
*
outcome / chisq (WARN=NOLOG) cellchi2 nopercent ; 
   output out=ChiSqData n pchi; 
   by j k; 
   weight y; 
   title 'Chi-Square Tests '; 
run; 
 
data result; 
set chisqdata; 
chi_1= (k)
*
_pchi_; 
chi_2= (k/2)
*
_pchi_; 
chi_3= (k/3)
*
_pchi_; 
chi_4= (k/4)
*
_pchi_; 
chi_5= (k/5)
*
_pchi_; 
run; 
 
 
/
*
//////////////////////////////////////// our values ///////////////////////////////////////////////
*
/ 
 
 
 
 
data result2; 
set result; 
if k=1 then do; 
if chi_1<3.8399 then reject1=0;else if chi_1>=3.8399then reject1=1; 
if chi_2<3.9152 then reject2=0;else if chi_2>=3.9152 then reject2=j; 
if chi_3<4.0191 then reject3=0;else if chi_3>=4.0191 then reject3=j; 
 
 
102 
 
if chi_4<4.0961then reject4=0;else if chi_4>=4.0961then reject4=j; 
if chi_5<4.1602then reject5=0;else if chi_5>=4.1602then reject5=j; 
end; else  
if k=2 then do; 
if chi_2<3.9152 then reject2=0;else if chi_2>=3.9152 then reject2=j; 
if chi_3<4.0191 then reject3=0;else if chi_3>=4.0191 then reject3=j; 
if chi_4<4.0961then reject4=0;else if chi_4>=4.0961then reject4=j; 
if chi_5<4.1602then reject5=0;else if chi_5>=4.1602then reject5=j; 
end; 
else 
if k=3 then do; 
if chi_3<4.0191 then reject3=0;else if chi_3>=4.0191 then reject3=j; 
if chi_4<4.0961then reject4=0;else if chi_4>=4.0961then reject4=j; 
if chi_5<4.1602then reject5=0;else if chi_5>=4.1602then reject5=j 
; 
end; 
else 
if k=4 then do; 
if chi_4<4.0961then reject4=0;else if chi_4>=4.0961then reject4=j; 
if chi_5<4.1602then reject5=0;else if chi_5>=4.1602then reject5=j; 
end; 
else 
if k=5 then do; 
if chi_5<4.1602then reject5=0;else if chi_5>=4.1602then reject5=j; 
end; 
run; 
data result3; 
set result2; 
by reject1 reject2 reject3 reject4 reject5 notsorted; 
if reject1=0 then stop1=0;else if reject1=1 then stop1=1;else stop1=.; 
if first.reject2 then if reject2 ne 0 then if reject2 ne . then do; stop2=k; reject2=1;end;else 
stop2=0;else stop2=0; else stop2=0; 
if first.reject3 then if reject3 ne 0 then if reject3 ne . then do; stop3=k; reject3=1;end;else 
stop3=0;else stop3=0;else stop3=0; 
if first.reject4 then if reject4 ne 0 then if reject4 ne . then do; stop4=k; reject4=1;end;else 
stop4=0;else stop4=0;else stop4=0; 
if first.reject5 then if reject5 ne 0 then if reject5 ne . then do; stop5=k; reject5=1;end;else 
stop5=0;else stop5=0;else stop5=0; 
run; 
 
data r1 r2 r3 r4 r5; 
set result3; 
by reject1 reject2 reject3 reject4 reject5 notsorted; 
if reject1=1 then output r1; 
if  reject2=1 then output r2; 
if  reject3=1 then output r3; 
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if  reject4=1 then output r4; 
if  reject5=1 then output r5; 
run; 
data r11; 
set r1  ; 
where k=1; 
run; 
 
data r21; 
set r2; 
by j; 
if first.j then output; 
run; 
data r31; 
set r3; 
by j; 
if first.j then output; 
run; 
data r41; 
set r4; 
by j; 
if first.j then output; 
run; 
data r51; 
set r5; 
by j; 
if first.j then output; 
run; 
data alpha; 
merge  r11 (in=in1) r21 (in= in2) r31 (in=in3) r41 (in=in4)r51 (in=in5); 
cutpoint="Our values"; 
 
bai1=&a; 
bai2=&a2; 
b=&b; 
n1=in1; 
n2=in2; 
n3=in3; 
n4=in4; 
n5=in5; 
run; 
data alpha2; 
set alpha; 
if n1=1 then c1+1; 
if n2=1 then c2+1; 
if n3=1 then c3+1; 
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if n4=1 then c4+1; 
if n5=1 then c5+1; 
a1=c1/&iterations; 
a2=c2/&iterations; 
a3=c3/&iterations; 
a4=c4/&iterations; 
a5=c5/&iterations; 
iterations=&iterations; 
run; 
data alpha_&bb (keep = iterations cutpoint bai1 bai2 b a1 a2 a3 a4 a5); 
set alpha2; 
by DF_PCHI; 
if last.DF_PCHI then output; 
run; 
proc print DATA=alpha_&bb; 
title  "results"; 
run; 
 
%end; 
%end; 
%mend alpha; 
%alpha 
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